A Droplet Digital Polymerase Chain Reaction (ddPCR) Approach for Sensitive and Non-Invasive Detection of Fetal Genetic Abnormalities.

A Thesis Submitted in Partial Fulfillment for the Requirement of the Award of the Degree of Master of Technology in Biotechnology

Submitted By

ISHITA

602304004

Under the Supervision of

Dr. Atul Thatai
Director
Molecular & Cytogenomics
Max Super Speciality Hospital
Saket, New Delhi

Dr Atul Kumar Upadhyay
Assistant Professor
Department of Biotechnology
Thapar Institute of Engineering & Technology
Patiala, Punjab

July 2025

DECLARATION

I hereby declare that the work presented in this dissertation, entitled "**A Droplet Digital Polymerase Chain Reaction (ddPCR) Approach for Sensitive and Non-Invasive Detection of Fetal Genetic Abnormalities"**, is the result of original research carried out by me in partial fulfillment of the requirements for the award of the degree of Master of Science in Biotechnology, under the supervision of **Dr. Atul Thatai**, Director Molecular & Cytogenomics, Max Super Speciality Hospital, Delhi and **Dr. Atul Kumar Upadhyay**, Assistant Professor, TIET Patiala.

The research work was conducted over a period of one year, from July 2024 to July 2025, and has not been submitted elsewhere for the award of any degree. I further declare that all sources of information and data have been duly acknowledged and that this dissertation is a genuine and independent contribution to scientific knowledge in the field.

Ishita
602304004
MTech. Biotechnology
Department of Biotechnology
Thapar Institute of Engineering and Technology, Patiala
July 2025

CERTIFICATE

This is to certify that the dissertation entitled "**A Droplet Digital Polymerase Chain Reaction (ddPCR)Approach for Sensitive and Non-Invasive Detection of Fetal Genetic Abnormalities**" submitted by Ms. Ishita (Roll No. 602304004) in partial fulfillment of the requirement for the award of the degree of Master of Science & Technology in Biotechnology, Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, Punjab, is an authentic record of students work during the period of one year from August 2024 to June 2025. This report has not been submitted for the reward of any other degree or certificate in this or any other university or institute.

DR. ATUL THATAI
Director
Molecular & Cytogenomics
Max Healthcare, New Delhi

DR. ATUL KUMAR UPADHYAY
Assistant Professor
Department of Biotechnology
TIET, Patiala

ACKNOWLEDGMENT

I hereby declare that the work presented in this dissertation, entitled "**Droplet Digital Polymerase Chain Reaction (ddPCR) Approach for Sensitive and Non-Invasive Detection of Fetal Genetic Abnormalities**", is an authentic record of my own research carried out in partial fulfillment of the requirements for the award of the degree of Master of Science in Biotechnology. The research work was conducted over a period of one year at the **Department of Genomics and Molecular Diagnostics**, Max Super Speciality Hospital, Delhi.

I would like to express my deepest gratitude to **Dr. Atul Thatai** and **Dr. Atul Kumar Upadhyay** for their invaluable guidance, constant encouragement, and insightful suggestions throughout the course of this project. His mentorship has been crucial to the successful completion of this work, and I am truly grateful for the opportunity to learn under his supervision.

My sincere appreciation goes to **Mr. Nishant Sharan** for his mentorship and continuous support in the lab. His patience, clarity in explaining complex concepts, and hands-on guidance have been vital to my learning and growth during this research journey.

I am also thankful to all my lab mates in the Genomics and Molecular Diagnostics Laboratory for their cooperation, encouragement, and for fostering a collaborative and motivating environment.

A heartfelt thank you to my parents, whose unwavering support, understanding, and encouragement 24/7 and throughout the year have been my greatest source of strength. Their belief in me has been the foundation of my perseverance and success. Also, my friends, their encouragement and humor have made this journey unforgettable.

Lastly, I would like to acknowledge the Department of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, for providing the academic foundation and institutional support necessary for undertaking this dissertation.

This work stands as a testament to the collective guidance, support, and belief of all those who stood by me throughout this journey.

"WHEN SCIENCE PROTECTS LIFE BEFORE IT BEGINS, IT SHAPES THE HEALTH OF GENERATIONS."

TABLE OF CONTENTS

S NO.	TITLE	PAGE NO.
1	DECLARATION	i
2	CERTIFICATION	ii
3	ACKNOWLRDGEMENT	iii
4	TABLE OF CONTENTS	iv
5	ABBREVATIONS	v
6	ABSTRACTS	vi
7	OBJECTIVES	vii
8	INTRODUCTION	1-4
9	REVIEW OF LITERATURE	5-38
10	MATERIALS AND METHODS	39-55
11	RESULTS & DISCUSSION	56-57
12	CONCLUSION	58
13	REFERENCES	59-66

ABBREVATIONS

S. No	Abbreviations	Full form
1	NIPT	Non-Invasive Prenatal Testing
2	cffDNA	cell-free fetal DNA
3	NGS	Next Generation Sequencing
4	CVs	Chorionic villus sampling
5	GMOs	Genetically Modified Organisms.
6	ddPCR	Droplet Digital Polymerase Chain Reaction.
7	LNAs	Locked Nucleic Acid
8	FF	Fetal Fraction
9	DMRs	Differentially Methylated Regions
10	CPM	Counts Per Million

ABSTRACT

Non-invasive prenatal testing (NIPT) has revolutionized the early detection of fetal genetic abnormalities, yet conventional platforms such as Next Generation Sequencing (NGS) are often constrained by cost, turnaround time, and operational complexity. This dissertation investigates the clinical utility and analytical performance of droplet digital PCR (ddPCR) as an alternative approach for targeted NIPT. Comparative analysis demonstrates that ddPCR consistently achieves high sensitivity and specificity 98% and 99%, respectively, for the detection of common chromosomal aneuploidies, values that are comparable to leading NGS methods. Importantly, ddPCR yields rapid results within approximately 90 minutes, significantly expediting clinical decision-making compared to the several days required for NGS workflows. The study also highlights the robustness of ddPCR in analyzing samples with low fetal DNA fractions, cost-effectiveness, and operational simplicity, making it accessible for use in both high-resource and resource-limited settings. However, ddPCR is best suited for the detection of known genetic targets, with genome-wide and exploratory diagnostics remaining the strength of NGS. Overall, ddPCR emerges as a sensitive, specific, rapid, and affordable tool for non-invasive prenatal detection of targeted fetal genetic abnormalities, with the potential to expand access to timely and accurate prenatal care. Further validation of multiplex ddPCR assays is recommended to broaden their clinical applicability.

OBJECTIVES

1. To evaluate the analytical sensitivity and specificity of droplet digital PCR (ddPCR) for the detection of common fetal genetic abnormalities, including trisomies 21, 18, and 13.
2. To compare the diagnostic performance of ddPCR with standard Next Generation Sequencing (NGS) methods in non-invasive prenatal testing (NIPT).
3. To assess the turnaround time and operational efficiency of the ddPCR workflow in comparison to conventional NGS-based prenatal testing.
4. To investigate ddPCR's ability to accurately detect fetal genetic abnormalities in samples with low fetal DNA fraction.
5. To analyze the cost-effectiveness and practical feasibility of implementing ddPCR as a routine clinical tool in diverse healthcare settings, including resource-limited environments.

CHAPTER 1

INTRODUCTION

Background and Importance of Prenatal Genetic Testing

Pregnancy is a journey filled with hope, anticipation, and the promise of new life. But it also comes with important decisions — choices that require accurate, safe, and timely information. Advances like cell-free fetal DNA testing and droplet digital PCR are helping to guide these decisions with greater confidence and sensitivity.

Prenatal genetic testing is a vital component of modern obstetric care that enables early detection of genetic abnormalities in the developing fetus. Fetal genetic disorders span a broad range, including chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13), as well as single-gene disorders like β-thalassemia, cystic fibrosis, and Duchenne muscular dystrophy. Accurate prenatal diagnosis offers expectant parents critical information for informed decision-making, pregnancy management, and preparation for potential healthcare needs of the newborn.

Historically, prenatal genetic testing began with invasive techniques such as amniocentesis, first clinically applied in 1956, and chorionic villus sampling (CVS) was introduced in the early 1980s. These procedures involve obtaining fetal cells through direct sampling of amniotic fluid or placental tissue, allowing definitive genetic diagnosis through karyotyping or molecular methods. Despite their diagnostic accuracy, these invasive methods carry a miscarriage risk ranging from approximately 0.1% to 1%, besides risks of infection or fetal injury. They also require specialized clinical settings and skilled personnel, limiting accessibility and increasing maternal anxiety.

The importance of early and precise detection of fetal abnormalities lies in its potential to reduce morbidity and mortality by guiding clinical interventions, optimizing delivery planning, and enabling genetic counseling. Moreover, the socio-economic impact of genetic disorders is considerable; affected children often require intensive medical care, long-term therapy, and special education, which impose emotional and financial burdens on families and healthcare systems.

Therefore, prenatal screening and diagnosis not only improve individual health outcomes but also contribute to public health by facilitating early interventions and resource allocation.

Evolution of Non-Invasive Prenatal Testing (NIPT)

A breakthrough in prenatal testing was the discovery of cell-free fetal DNA (cffDNA) in maternal plasma, first reported in 1997. cffDNA is released into the maternal bloodstream primarily from apoptotic placental trophoblasts and constitutes about 5-20% of total circulating cell-free DNA during pregnancy. This discovery paved the way for non-invasive prenatal testing (NIPT), which analyzes fetal genetic material without the risks associated with invasive sampling.

Early NIPT methods employed real-time quantitative PCR (qPCR) targeting specific fetal DNA sequences but faced challenges due to low fetal DNA fraction and high maternal DNA background. Microarray-based techniques improved genomic coverage but still lacked sensitivity for detecting low-frequency variants. The advent of next-generation sequencing (NGS) in the early 2010s revolutionized NIPT, enabling genome-wide analysis of fetal chromosomal aneuploidies with high accuracy.

Although NGS-based NIPT offers improved detection rates and is widely adopted clinically, it has limitations, including high cost, longer turnaround times, complexity of data analysis, and requirements for advanced laboratory infrastructure. These factors limit availability, especially in resource-constrained settings and for wider application beyond aneuploidy screening.

Introduction to Droplet Digital PCR (ddPCR) Technology

Droplet Digital PCR (ddPCR) is a third-generation PCR technology that enhances nucleic acid quantification precision by partitioning a PCR reaction into tens of thousands of nanoliter-sized droplets. Each droplet acts as an independent PCR microreactor. After amplification, droplets are analyzed individually for fluorescence signals indicating the presence or absence of target DNA sequences.

Key technical components of ddPCR include the droplet generator, which partitions the PCR mixture; the PCR thermocycler; and the droplet reader that performs fluorescence detection. This partitioning transforms the quantitative PCR into a digital readout, where Poisson statistical analysis allows absolute quantification of target DNA copies without calibration curves.

Compared to conventional PCR and qPCR, ddPCR offers several advantages for fetal DNA detection:

- Superior sensitivity and specificity: Capable of detecting rare target sequences amid abundant background DNA, crucial for low fetal fraction cffDNA.
- Absolute quantification: Facilitates precise measurement of DNA copy numbers, improving detection accuracy for genetic abnormalities.
- Robust against PCR inhibitors and sample variability.
- Cost-effective and faster turnaround compared to NGS, with simpler data analysis.

These attributes render ddPCR a highly suitable platform for non-invasive prenatal diagnosis, especially when targeting specific mutations, aneuploidies, or polymorphisms in the fetal genome.

Applications of ddPCR in Prenatal Diagnosis

ddPCR is increasingly employed for various prenatal diagnostic applications:

- Chromosomal Aneuploidy Detection: ddPCR assays can accurately quantify relative chromosome dosage, detecting trisomies such as 21, 18, and 13 with high sensitivity.
- Single-Gene Disorder Identification: Targeted ddPCR detects pathogenic variants for monogenic diseases like β-thalassemia and cystic fibrosis, enabling early carrier screening and fetal risk assessment.
- Fetal Sex Determination and RhD Genotyping: ddPCR facilitates non-invasive determination of fetal sex and Rhesus D status, which are critical for managing hemolytic diseases.
- Comparison with Other Methods: ddPCR offers cost and time advantages over NGS, with potentially broader accessibility in clinical laboratories lacking NGS infrastructure.

Recent Trends and Innovations in ddPCR for NIPT

Recent advances in ddPCR technology extend its application and enhance its diagnostic power:

- Single cell ddPCR: Isolation and analysis of intact fetal cells from maternal blood enable direct fetal genome interrogation, complementing cffDNA testing.

- Multiplex ddPCR: Simultaneous amplification of multiple targets increases throughput and diagnostic breadth.
- Integration with Artificial Intelligence and Bioinformatics: Enhances interpretation of complex fluorescence data patterns and fragmentomics to better distinguish fetal versus maternal DNA.
- Fragment omics Research: Studies on size, methylation, and fragmentation patterns of cffDNA provide new biomarkers to improve fetal DNA discrimination and disease detection.

Challenges and Future Perspectives

While ddPCR shows great promise for sensitive, non-invasive prenatal diagnosis, several challenges remain:

- Technical issues: DNA fragmentation, low fetal fractions, and allelic dropout can affect assay accuracy.
- Ethical and regulatory considerations: The expansion of prenatal genetic testing raises concerns about informed consent, privacy, and potential discrimination.
- Implementation in low-resource settings: Despite cost advantages over NGS, technical expertise and equipment costs may hinder adoption.
- Integration with other diagnostic tools: Combining ddPCR with sequencing and imaging modalities could enhance prenatal care.
- Future prospects: Personalized prenatal medicine with real-time monitoring, expanded panels for genetic disorders, and point-of-care platforms represent future directions.

This comprehensive introduction sets the stage for your thesis on ddPCR-based non-invasive prenatal detection of fetal genetic abnormalities, providing historical context, technological evolution, current applications, and future outlook.

CHAPTER -2

REVIEW OF LITERATURE

Overview of Non-Invasive Prenatal Testing (NIPT)

- Overview of Non-Invasive Prenatal Testing (NIPT)
- Importance of Detecting Fetal Aneuploidies
- Role of Droplet Digital PCR (ddPCR) in NIPT

Non-Invasive Prenatal Testing (NIPT) is a revolutionary screening method designed to assess the risk of chromosomal abnormalities in fetuses using cell-free fetal DNA (cffDNA) in maternal blood. Since its introduction in 2011, NIPT has transformed prenatal care by offering a safer, highly accurate, and non-invasive alternative to traditional diagnostic methods such as amniocentesis and chorionic villus sampling (CVS) [1] [2].

What is NIPT?

NIPT analyzes cfDNA originating from the placenta, which circulates in the maternal bloodstream. This DNA provides genetic information about the fetus, enabling screening for conditions such as:

- Trisomy 21 (Down syndrome): The most common chromosomal abnormality detected.
- Trisomy 18 (Edwards syndrome).
- Trisomy 13 (Patau syndrome) [3] [4].

In addition to these aneuploidies, NIPT can detect other chromosomal abnormalities like Turner syndrome and Klinefelter syndrome, and it can predict fetal sex with high accuracy. [4].

Procedure

NIPT involves a simple blood draw from the pregnant woman, typically performed as early as 10 weeks into pregnancy. The cffDNA is extracted and analyzed using advanced genomic technologies such as next-generation sequencing (NGS). This process identifies chromosomal abnormalities with a high degree of sensitivity and specificity. [5] [2].

Advantages of NIPT

1. Non-Invasiveness: Unlike invasive diagnostic tests (e.g., amniocentesis), NIPT poses no physical risk to the fetus or pregnancy [3] [1].

2. High Accuracy: NIPT offers over 99% accuracy for detecting common chromosomal conditions, significantly reducing false positives and false negatives compared to traditional screening methods [3] [6].

3. Early Detection: Results are available earlier in pregnancy (around 10 weeks), providing parents more time for decision-making [6] [2].

4. Wide Applicability: Suitable for high-risk pregnancies, including those involving advanced maternal age, history of genetic conditions, or assisted reproductive technologies [3] [4].

Limitations

Despite its advantages, NIPT has certain limitations:

1. Screening vs. Diagnosis: NIPT is a screening tool that estimates risk but does not provide definitive diagnoses. Positive results require confirmation through invasive diagnostic tests like amniocentesis or CVS [3] [1].
2. Restricted Scope: While effective for detecting common aneuploidies, NIPT cannot identify all genetic disorders or structural anomalies [3] [5].
3. False Positives/Negatives: Rarely, results may be inaccurate due to factors such as placental mosaicism or maternal conditions [1] [2].

Clinical Applications

NIPT has been widely adopted in clinical practice for various purposes:

1. Aneuploidy Screening: Detecting trisomies and sex chromosome abnormalities.

2. Fetal Sex Determination: Predicting fetal sex with high precision.

3. Monogenic Disorders: Emerging technologies now allow screening for single-gene disorders using multi-gene sequencing techniques [4].

4. Reducing Invasive Testing: By lowering false-positive rates, NIPT reduces the need for invasive procedures and associated risks like miscarriage [6].

Ethical Considerations

The widespread use of NIPT raises ethical concerns:

1. Reproductive Autonomy: Pregnant women must have access to comprehensive genetic counseling to make informed decisions about testing and subsequent actions [1] [7].
2. Disability Stigma: Increased use of prenatal screening may inadvertently reinforce societal biases against individuals with disabilities [7].
3. Consent and Privacy: Ensuring informed consent and protecting sensitive genetic information are critical challenges in implementing NIPT at scale [6] [7].

Impact on Healthcare Systems

NIPT has significantly influenced prenatal care pathways:

In publicly funded healthcare systems like the NHS in England, its integration has improved accessibility and reduced reliance on invasive testing methods. For example, uptake increased from 39% privately funded tests to 86% under NHS funding since its inclusion in 2021 [8].Cost-effectiveness studies suggest that while NIPT is more expensive than traditional screening methods, its accuracy and non-invasiveness make it a valuable tool for high-risk pregnancies [3] [6].

Advancements in Technology

Recent innovations have expanded the capabilities of NIPT:

- The incorporation of next-generation sequencing (NGS) enables the detection of sub-chromosomal abnormalities and single-gene disorders.
- Multi-gene sequencing platforms are now commercially available to screen for inherited conditions beyond aneuploidies [5] [2].

Future Prospects

The future of NIPT lies in further technological advancements and broader implementation:

1. Expanded Screening Panels: Development of assays that detect a broader range of genetic conditions.
2. Cost Reduction: Making NIPT affordable for routine use in low-resource settings.
3. Global Standardization: Establishing universal guidelines for ethical implementation and informed consent practices.

Technological Background

- Principles of ddPCR Technology
- Advantages of ddPCR Over Conventional PCR and NGS

Multiplexing in ddPCR: Concept and Applications

The evolution of molecular biology has been profoundly shaped by the introduction of the polymerase chain reaction (PCR), a technique that revolutionized our ability to amplify specific DNA sequences. [9]. However, as scientific inquiries demanded greater sensitivity, accuracy, and quantitative power, traditional PCR methods began to reveal their limitations, particularly when detecting low-abundance genetic targets or subtle mutations.

In response to these challenges, droplet digital PCR (ddPCR) has emerged as a transformative advancement in nucleic acid quantification. By partitioning DNA samples into thousands of individual droplets and allowing PCR within each one, ddPCR enables precise, absolute quantification a significant departure from the relative quantification used in conventional qPCR. Since its debut by Hindson and colleagues in 2011, ddPCR has found applications in fields ranging from oncology and infectious disease diagnostics to environmental science and agriculture.

Fundamental Principles of ddPCR Technology

At the core of ddPCR lies a deceptively simple yet powerful concept: sample partitioning. Unlike traditional PCR, which amplifies DNA in a single reaction mixture, ddPCR divides the reaction into approximately 20,000 nanoliter-sized droplets using a water-oil emulsion. [10]. Each droplet acts as an independent reaction chamber that may or may not contain a target DNA molecule.

Once partitioned, the droplets undergo thermal cycling. Amplification occurs only in droplets where the target sequence is present. After PCR, droplets are streamed individually through a

reader that uses fluorescence to distinguish positive droplets (with amplification) from negative ones (without amplification).

The results are interpreted using Poisson statistical models, which estimate the original concentration of the target nucleic acid based on the number of positive and negative droplets. This bypasses the need for calibration curves, enabling absolute quantification with high precision. [11].

Every droplet is like a mini laboratory, giving scientists thousands of chances to find what they're looking for, even if it's rare.

Why ddPCR Outperforms Conventional PCR and NGS

- Absolute Quantification Without Calibration

  One of the most celebrated features of ddPCR is its ability to quantify nucleic acids absolutely, without relying on standard curves. This makes ddPCR less susceptible to variations introduced by fluctuating standards or reference genes, a significant advantage over qPCR [12]. This precision is particularly valuable in clinical diagnostics, where reliability is non-negotiable.

- Unmatched Sensitivity and Specificity

  ddPCR shines when detecting rare events, such as somatic mutations in cancer or low-level viral loads. The technique has been shown to detect mutant alleles at frequencies as low as 0.001%, a capability far beyond the detection limit of qPCR [13].

  This has made ddPCR a go-to method for liquid biopsy, where circulating tumor DNA must be detected against a high background of normal DNA   a needle-in-a-haystack scenario where ddPCR excels.

- Tolerance to Inhibitors in Complex Samples

- Real-world biological samples often contain compounds that inhibit PCR, like heparin in blood or humic acids in soil. ddPCR's droplet-based partitioning effectively dilutes the impact of these inhibitors, allowing for more accurate detection under challenging matrices [14].

Compared to NGS: Precision vs Breadth

While next-generation sequencing (NGS) is ideal for broad profiling and discovering unknown mutations, ddPCR offers superior precision when specific targets are already known. It also boasts shorter turnaround times and lower costs, and it is better suited for rapid, targeted applications such as tracking viral loads or monitoring minimal residual disease. [15].

Think of NGS as a wide-angle camera lens and ddPCR as a zoom lens: both are powerful, but for different tasks.

Multiplexing in ddPCR: Principles and Practical Applications -

Concept of Multiplexing in ddPCR-

Multiplexing in ddPCR refers to detecting multiple targets in a single reaction well a feat achieved by using fluorescent probes with distinct emission spectra or adjusting fluorescence amplitude. For instance, a reaction might detect both a reference gene and a mutation simultaneously, or even differentiate among several mutations in a single oncogene. [16].

Recent advances in fluorescence chemistry and droplet-readout technology allow ddPCR systems to support triplex or even four-plex detection, vastly expanding their utility.

Working Mechanism of ddPCR-

Droplet Digital PCR (ddPCR) works by partitioning a DNA (or RNA) sample into thousands of nanoliter-sized water-in-oil droplets, each acting as a separate micro-PCR reaction. PCR amplification occurs independently in each droplet, and after thermal cycling, a fluorescence detector scores each droplet as either positive (containing amplified target) or negative (no target), enabling highly sensitive and absolute quantification of target molecules.

Key steps and mechanisms:

- The sample, containing template nucleic acids, primers, probes, nucleotides, enzymes, and buffers, is divided into around 20,000 individual droplets using water-in-oil emulsion microfluidic technology.
- Each droplet acts as an individual PCR microreactor. Some droplets contain zero, one, or more copies of the target sequence; most droplets will contain none or one, following a random (Poisson) distribution.
- Standard PCR amplification (thermocycling) is performed on all droplets simultaneously.
- After amplification, droplets are passed through an optical detection system. Droplets with amplified product emit a fluorescent signal ("on" or positive), while those without the target remain dark ("off" or negative).
- The number of "on" (fluorescent) versus "off" droplets is counted. Since the distribution is random, Poisson statistics are used to correct for the possibility that some droplets started with more than one target molecule, providing an absolute quantification of the starting copy number.

The Poisson distribution is a probability model used to describe the number of times an event happens in a fixed interval of time or space, assuming these events happen independently and at a constant average rate.

In ddPCR**,** the Poisson distribution helps calculate how likely it is that a droplet contains zero, one, or more target molecules. This allows correction for droplets that might have more than one target, enabling accurate, absolute quantification.

Key points:

Used for count data over a fixed period or region.

Assumes independent events and a constant rate.

The mean and variance are both equal to λ

Applications of Multiplex ddPCR

Clinical Diagnostics-

Multiplex ddPCR is particularly well-suited to diagnosing infections involving co-infections or multiple pathogens. One study demonstrated the simultaneous detection of five biothreat bacterial agents with a single ddPCR assay, reducing costs and time. [17].

Similarly, multiplex assays from a single patient sample can screen for genetic mutations in diseases like cystic fibrosis, thalassemia, or BRCA-related cancers.

Cancer Genomics-

In oncology, ddPCR's ability to multiplex allows for multi-mutation profiling of circulating tumor DNA, facilitating real-time monitoring of therapy response and detection of resistance mutations, for example, in EGFR, KRAS, and BRAF genes. [18].

Environmental and Agricultural Monitoring-

In environmental microbiology, multiplex ddPCR is used to quantify microbial diversity, detect gene flow of antibiotic resistance markers, and monitor water safety. [19]. In agriculture, it helps detect genetically modified organisms (GMOs) and plant pathogens across multiple species in one go.

Droplet Digital PCR represents a mighty leap forward in molecular quantification, offering absolute, highly sensitive, and reproducible measurements that outperform conventional PCR techniques and complement high-throughput methods like NGS. Multiplexing capabilities further enhance its utility, which allows simultaneous analysis of multiple targets, saving time, sample material, and costs.

As ddPCR technology matures and instrumentation becomes more accessible, its integration into mainstream clinical, environmental, and research settings will likely accelerate, solidifying its role as a cornerstone of next-generation molecular diagnostics.

Development of Multiplex ddPCR Assays

- Use of Locked Nucleic Acid (LNA) Probes in ddPCR
- Primer and Probe Design for Chromosomal Targets
- Statistical Optimization: Poisson Distribution for Droplet Analysis

Droplet digital PCR (ddPCR) represents a significant advancement in nucleic acid quantification, offering unparalleled precision, sensitivity, and absolute quantification without needing external calibrators. Unlike traditional quantitative PCR (qPCR), which relies on relative quantification using standard curves, ddPCR partitions a single PCR reaction into thousands to millions of nanoliter-sized droplets. Each droplet functions as a micro reaction, allowing binary (positive or negative) endpoint detection. The number of target DNA or RNA molecules can be estimated with high accuracy and reproducibility through statistical modeling based on the Poisson distribution.

Since its inception, ddPCR has been increasingly utilized in various fields, including oncology, infectious diseases, environmental monitoring, prenatal diagnostics, and gene editing validation. [20]. The ability to detect rare variants and quantify low-copy targets makes ddPCR particularly valuable in settings where sensitivity and specificity are paramount. However, for ddPCR to realize its full potential in high-throughput or multi-targeted diagnostics, the development of robust multiplex assays becomes critical. Multiplexing, or the simultaneous detection of multiple targets within a single ddPCR reaction, offers several advantages, such as reduced sample volume requirements, faster processing times, and cost-effectiveness. Nonetheless, this approach also presents unique technical challenges that necessitate rigorous optimization of assay design, probe chemistry, and statistical interpretation.

This literature review explores four central pillars of ddPCR assay development-

(1) the evolution and strategies behind multiplex ddPCR assays,

(2) the incorporation of Locked Nucleic Acid (LNA) probes to enhance assay performance,

(3) the meticulous design of primers and probes for targeting chromosomal sequences, and

(4) The role of statistical modeling, particularly the Poisson distribution, in analyzing and optimizing droplet partitioning data.

Overview of Multiplexing in ddPCR

Multiplex ddPCR allows for detecting multiple nucleic acid targets within a single reaction well, utilizing partitioned droplets to amplify target sequences tagged with distinct fluorophores independently. Each fluorescent channel in the system (e.g., FAM, HEX, Cy5) can be used to monitor a specific target, while variations in probe concentration and amplitude further allow for subchannel multiplexing. [21].

This approach is desirable in clinical diagnostics where comprehensive profiling of multiple biomarkers is necessary. For example, in liquid biopsy applications for cancer, it is often critical to detect numerous oncogenic mutations simultaneously [22]. In infectious disease testing, multiplexing permits the detection of co-infections or differential diagnosis of similar pathogens within a single run [23].

Technical Challenges in Multiplex ddPCR

Despite its advantages, developing reliable multiplex ddPCR assays presents several technical obstacles. One of the significant issues is fluorescence spillover, where emission from one probe's dye bleeds into another channel, potentially resulting in false-positive droplets or unclear cluster separation. This can be mitigated by selecting fluorophores with minimal spectral overlap and applying software-based compensation techniques [13].

Another challenge is competition among primers and probes. When multiple primers and probes are included in a single reaction, they may compete for polymerase, dNTPs, or binding sites, leading to uneven amplification efficiency and reduced sensitivity for specific targets. To address this, empirical optimization of primer/probe concentrations, annealing temperatures, and cycling conditions is essential [24].

Additionally, template abundance disparities can cause dominant targets to overshadow low copy targets in droplet fluorescence intensity, complicating data interpretation. Carefully balancing input DNA concentration and designing reactions within the optimal range for Poisson-based modeling ($\lambda < 1$) is crucial to maintaining assay linearity and accuracy.

Strategies to Improve Multiplex Performance

Several strategies have been proposed to enhance multiplex ddPCR assay performance. These include:

1) Amplitude-based multiplexing, where different concentrations of the same dye-labeled probe produce distinct fluorescence intensities [25].

2) Ratio metric approaches, utilizing dual-labeled probes or target ratios to improve signal resolution [26].

3) Thermal cycling optimization, where minor temperature adjustments can harmonize primer annealing across different targets [11].In addition, the use of custom-designed probes with locked **[27]** Nucleic acids (LNAs) have been shown to enhance mismatch discrimination and cluster tightness, thereby improving target separation. This will be discussed in detail in Section 2.3.

Applications of Multiplex ddPCR

Recent applications of multiplex ddPCR demonstrate its utility across a broad spectrum of fields. For example:

- Oncology: Detection of KRAS, BRAF, and EGFR mutations in plasma for non-invasive tumor genotyping [28].
- Infectious Diseases: Simultaneous quantification of multiple viral loads (e.g., HIV, HBV, HCV) from a single blood sample [29].
- Prenatal Testing**:** Combined screening for trisomy 13, 18, and 21 using chromosome-specific assays [27] .
- Agri genomics**:** Quantification of genetically modified organisms (GMOs) in food samples [30].

These studies exemplify the growing relevance of multiplex ddPCR in translational and applied research settings.

Use of Locked Nucleic Acid (LNA) Probes in ddPCR

Introduction to LNA Chemistry

Locked Nucleic Acids (LNAs) are a class of nucleic acid analogs in which the ribose ring is chemically constrained by a methylene bridge connecting the 2′ oxygen and the 4′ carbon. This conformational "lock" confers increased thermal stability and binding affinity to complementary DNA or RNA strands, making LNA-modified oligonucleotides particularly valuable in applications requiring high specificity and sensitivity [31].

LNAs have revolutionized molecular diagnostics by enabling the discrimination of single-nucleotide mismatches with exceptional precision. Their unique structure results in a significant increase in melting temperature (Tm), typically 2 to 8°C per LNA residue, thereby allowing shorter probes to achieve strong hybridization under stringent conditions [32]. When incorporated into hydrolysis probes (e.g., TaqMan probes), LNA modifications enhance probe-target stability, reduce background noise, and sharpen cluster separation in ddPCR readouts.

Benefits of LNA Probes in ddPCR

The incorporation of LNA bases into ddPCR probes offers numerous benefits:

- **Enhanced Mismatch Discrimination:** LNA probes can distinguish between perfectly matched and mismatched sequences with high fidelity, making them ideal for detecting rare mutations or single-nucleotide polymorphisms (SNPs) [33].
- **Increased Sensitivity in Low-Copy Targets:** Due to improved binding kinetics, LNA probes can hybridize more efficiently even at low template concentrations, which is crucial in ddPCR applications such as circulating tumor DNA (ctDNA) detection [34].
- **Improved Cluster Resolution:** Tighter probe-target binding leads to more defined positive and negative droplet clusters, reducing ambiguous signal interpretation in multiplex ddPCR formats [35].
- **Shorter Probe Design:** LNA incorporation allows the use of shorter probes without sacrificing hybridization strength, useful in regions with limited sequence space (e.g., exon boundaries or small indels).

Design Considerations for LNA Probes

Designing LNA probes for ddPCR requires careful attention to balance affinity and specificity. Over-modification can lead to overly stable probe-target hybrids, risking reduced mismatch discrimination or inefficient hydrolysis during amplification.

Best practices for LNA probe design include:

- Incorporating LNA bases primarily at central positions of the probe.
- Limiting LNA content to 20-30% of total bases.
- Avoiding LNA placement at probe ends or near fluorophore/quencher sites, which may impair fluorescence efficiency [36].

It is also essential to perform *in silico* modeling and empirical validation, as Tm predictions for LNA probes can vary depending on sequence context and local secondary structures.

Applications of LNA Probes in ddPCR

LNA probes have demonstrated exceptional performance in several ddPCR-based applications. For instance:

- Cancer Genotyping**:** LNA-modified probes have been used to detect EGFR T790M resistance mutations in non-small cell lung cancer (NSCLC) with high sensitivity in plasma samples [37].
- Infectious Disease Diagnostics**:** In hepatitis B virus (HBV) monitoring, LNA probes enable the detection of quasispecies and resistance-associated mutations at low abundance [38].
- Non-Invasive Prenatal Testing (NIPT)**:** LNA-based assays have improved the detection of fetal aneuploidies and point mutations in cell-free fetal DNA [39].
- Gene Editing Validation: ddPCR using LNA probes can distinguish between edited and unedited alleles with single-nucleotide resolution, enhancing quality control in CRISPR workflows [40].

  These examples underscore the versatility and robustness of LNA probes in ddPCR, particularly in scenarios requiring exceptional accuracy for rare target detection.

Clinical Applications

- Detection of Common Aneuploidies (e.g., Trisomy 21, 18, 13)
- Validation Studies on Maternal Plasma Samples
- Applications Beyond Aneuploidies: Monogenic Disorders and Blood Group Testing

Non-invasive prenatal testing (NIPT) has revolutionized prenatal care by enabling the detection of fetal genetic conditions through the analysis of cell-free fetal DNA (cffDNA) in maternal plasma. Among the various technologies employed in NIPT, droplet digital PCR (ddPCR) has emerged as a powerful tool due to its high sensitivity, specificity, and absolute quantification capability without the need for standard curves [41]. This review explores the clinical applications of ddPCR in NIPT, focusing on the detection of common aneuploidies, validation studies on maternal plasma samples, and its expanding role in diagnosing monogenic disorders and determining fetal blood group genotypes.

Detection of Common Aneuploidies (Trisomy 21, 18, 13)

Trisomy 21 (Down Syndrome)

Trisomy 21, or Down syndrome, is the most prevalent chromosomal aneuploidy, occurring in approximately 1 in 700 live births. Early detection is crucial for informed decision-making and management. ddPCR allows for precise quantification of chromosome 21-specific sequences in maternal plasma, facilitating accurate detection of trisomy 21[42]. Demonstrated that ddPCR could detect trisomy 21 with high sensitivity and specificity, comparable to or exceeding traditional quantitative PCR methods.

Trisomy 18 (Edwards Syndrome) and Trisomy 13 (Patau Syndrome)

Trisomy 18 and 13 are associated with severe developmental anomalies and high perinatal mortality. ddPCR has been effectively utilized to detect these aneuploidies by targeting specific sequences on chromosomes 18 and 13. The technology's ability to partition DNA samples into thousands of droplets enhances its sensitivity, enabling the detection of subtle variations in chromosome copy numbers indicative of these trisomies [42].

Validation Studies on Maternal Plasma Samples

Validation of ddPCR for NIPT involves assessing its performance in detecting fetal genetic material amidst a background of maternal DNA. Several studies have evaluated ddPCR's efficacy in this context:

A study by Perlado et al. (2016) demonstrated that ddPCR could accurately detect both paternally and maternally inherited fetal alleles in maternal plasma, achieving 100% accuracy for paternal alleles and 96% for maternal alleles using relative mutation dosage analysis.

A multicenter study involving over 68,000 pregnancies showed that NIPT using ddPCR provided high sensitivity and specificity for detecting trisomies 21, 18, and 13, underscoring its reliability in clinical settings. [43].

These studies highlight ddPCR's robustness in analyzing maternal plasma samples, affirming its suitability for routine NIPT applications.

Applications Beyond Aneuploidies

Monogenic Disorders

Beyond chromosomal aneuploidies, ddPCR has been instrumental in the non-invasive detection of monogenic disorders:

- Sickle Cell Disease and Thalassemia: ddPCR enables the detection of specific point mutations responsible for hemoglobinopathies, facilitating early diagnosis and management [41].
- Cystic Fibrosis: By targeting known mutations in the CFTR gene, ddPCR allows for the non-invasive prenatal diagnosis of cystic fibrosis, particularly when one or both parents are carriers [43].
- Other Single-Gene Disorders: ddPCR's high sensitivity makes it suitable for detecting mutations associated with a range of monogenic disorders, including Duchenne muscular dystrophy and spinal muscular atrophy [41].

Blood Group Testing

Determining fetal blood group antigens non-invasively is critical in managing pregnancies at risk of hemolytic disease of the fetus and newborn (HDFN):

- RhD Genotyping: ddPCR has been successfully employed to determine fetal RhD status from maternal plasma, guiding the administration of anti-D immunoglobulin to prevent alloimmunization [44].
- Other Blood Group Antigens: Wang et al. (2023) extended ddPCR applications to predict fetal Ss, Kidd, and CTL2 blood groups, demonstrating accurate genotyping that aligns with postnatal serological findings.

These applications underscore ddPCR's versatility in prenatal diagnostics, offering non-invasive solutions for a broad spectrum of genetic assessments.

Challenges in ddPCR-Based NIPT

- Low Fetal DNA Fraction and Its Impact on Accuracy
- False Positives and False Negatives in ddPCR Assays
- Technical Limitations in High-Multiplex Assays

Non-invasive prenatal testing (NIPT) using droplet digital PCR (ddPCR) has emerged as a promising alternative to next-generation sequencing (NGS), offering cost-effectiveness and rapid turnaround times. However, its clinical adoption faces significant biological variability, technical limitations, and analytical complexity challenges. Below, we review these hurdles, focusing on low fetal DNA fraction, false results, and high-multiplex assay constraints.

Low Fetal DNA Fraction and Diagnostic Accuracy

The fetal fraction (FF), the proportion of cell-free fetal DNA (cffDNA) in maternal plasma, critically influences ddPCR's reliability. Studies show that FF below 4% increases the risk of misdiagnosis, particularly for conditions like trisomy 18, where sensitivity drops to 90% compared to 98% for trisomy 21 [45]. Low FF reduces the statistical power to detect fetal-specific alleles or chromosomal abnormalities. For example, in a ddPCR-based genotyping study, 5/38 samples yielded inconclusive results due to insufficient FF or positive droplets. [46].

Strategies to mitigate low FF include:

- Sequencing shorter cffDNA fragments (107-145 bp) enriches fetal DNA by leveraging its smaller size compared to maternal DNA. This method boosted FF from 3.4% to 15.48% in obese patients and those with early gestational age [47].
- Methylation-based assays targeting fetal-specific differentially methylated regions (DMRs). These approaches circumvent FF dependency on SNPs or fetal sex, achieving accurate FF estimation even at low levels.

Despite these advances, biological factors like confined placental mosaicism (CPM) can distort FF measurements, leading to false positives and negatives. [45].

False Positives and Negatives in ddPCR Assays

False results in ddPCR-based NIPT arise from technical and biological factors:

1. Low FF and Allelic Drop-out:
   In a study of 124 maternal plasma samples, 2 cases were misclassified as false negatives for sickle cell disease and false positives for an X-linked variant, highlighting the risk of allelic imbalance detection errors at low FF [48].
2. CPM and Placental Discordance:
   Discordance between placental and fetal genotypes due to CPM can lead to false positives if abnormal placental DNA dominates cffDNA or false negatives if mosaic signals are diluted [45].
3. Threshold Variability:
   Probabilistic models using sequential probability ratio testing (SPRT) or Bayesian analysis reduce but do not eliminate errors. In one cohort, these methods achieved 96-98% correct predictions but left 31% of cases inconclusive. [48].
4. Technical Artifacts:
   Suboptimal probe design or target selection can skew copy number ratios. For instance, in a trisomy 21 ddPCR assay, improper cutoff values initially caused false results, which were later resolved in validation phases. [49].

Technical Limitations in High-Multiplex ddPCR Assays

While ddPCR excels in targeted testing, scaling it for high-multiplex applications remains challenging:

1. Fluorophore Limitations:
   Most ddPCR systems use 2-4 fluorescence channels, restricting multiplexing capacity. For example, a trisomy 21 assay using two fluorophores (one for chromosome 21, another for a reference chromosome) required careful normalization to avoid signal overlap. [49].

2. Reaction Partitioning Efficiency:
   Achieving uniform partitioning of DNA templates across thousands of droplets is technically demanding. Inadequate partitioning reduces the effective number of reactions, lowering sensitivity for low-abundance targets. [45].

3. Data Complexity:
   Analyzing multiplexed ddPCR data requires advanced statistical models. A comparative study of SPRT, Bayesian, and z-score methods revealed that all struggled with samples near decision thresholds, leading to inconclusive results. [48].

4. Cost and Scalability:
   While ddPCR costs (~USD 100 per test) are lower than NGS (~USD 570), scaling multiplex assays increases reagent and labor expenses. For example, detecting 22q11.2 deletions required six simultaneous reactions, raising complexity and cost [45].

Future Directions

Combining ddPCR with NGS could optimize NIPT workflows: NGS for broad screening and ddPCR for validating high-risk cases6. Additionally, advancements in microfluidic partitioning, artificial intelligence-driven analysis, and methylation-based FF estimation may address current limitations. For instance, methylation-sensitive assays reduced FF variability in a 2019 study, improving aneuploidy detection accuracy.

ddPCR-based NIPT offers a rapid, cost-effective alternative to NGS but faces critical challenges with low fetal DNA fractions, analytical variability, and multiplexing constraints. While innovations in fragment size selection, methylation analysis, and probabilistic modeling have

improved reliability, biological factors like CPM and technical hurdles in high-plex assays remain unresolved. Collaborative approaches integrating multiple technologies and robust validation protocols will be essential to advance non-invasive prenatal diagnostics.

Comparative Analysis

- ddPCR vs Next-Generation Sequencing (NGS) for NIPT
- Cost, Speed, and Accessibility Comparisons
- Performance Metrics: Sensitivity, Specificity, and Positive Predictive Value

Non-invasive prenatal testing (NIPT) has revolutionized prenatal care, with droplet digital PCR (ddPCR) emerging as a cost-effective challenger to next-generation sequencing (NGS). While both technologies analyze cell-free fetal DNA (cfDNA), their performance, scalability, and economic profiles differ significantly. Below, we compare their clinical utility across key metrics.

ddPCR Advantages:

- Per-test cost: $110-$570 for ddPCR vs. $200-$1,100 for NGS, with large-scale ddPCR potentially dropping below $100 [45].
- Infrastructure: ddPCR requires minimal bioinformatics support, reducing capital costs by ~82% compared to NGS ($16,411 vs. $91,440 annually)[50].
- Reagent expenses: Multiplexed ddPCR assays cost 60-70% less per reaction than NGS library preparation.

NGS Limitations:

- High-throughput sequencing platforms and skilled personnel account for 65% of NGS costs.
- Bioinformatic analysis adds $50-$150 per sample, a cost absent in ddPCR workflows [45].

A 2024 Indian study found ddPCR reduced annual testing costs by 62% for 2,400 samples, making it viable for low-resource settings[50].

Speed and Workflow Efficiency-

Metric	ddPCR	NGS
Turnaround time	4-8 hours	3-7 days
Hands-on time	1-2 hours	6-8 hours
Data analysis	Automated (15-30 mins)	Complex pipeline (2-4 hours)

ddPCR's end-point quantification eliminates time-consuming sequencing steps, enabling same-day results critical for late-gestation diagnoses[45, 51]. NGS workflows remain bottlenecked by library preparation and computational analysis.

Performance Metrics-

Sensitivity and Specificity-

- **Trisomy 21**:
  - ddPCR: 98% sensitivity, 99% specificity.
  - NGS: 99.3% sensitivity, 99.9% specificity.
- **Trisomy 18**:
  - ddPCR: 90% sensitivity, 99.6% specificity.
  - NGS: 96% sensitivity, 99.8% specificity.

Key limitation: ddPCR's sensitivity drops below 4% fetal fraction (FF), while NGS maintains >95% accuracy down to 2% FF [45].

Positive Predictive Value (PPV)

- ddPCR: 85-92% for h 13/18/21 in mixed-risk cohorts.
- NGS: 93-99% across all major aneuploidies.

NGS's genome-wide analysis provides superior PPV for rare microdeletions, whereas ddPCR excels in targeted high-prevalence conditions.

ddPCR Strengths:

- Operates in basic PCR labs without specialized sequencing facilities
- Minimal training required compared to NGS bioinformatics expertise[51].
- Portable platforms enable point-of-care testing in rural areas.

NGS Barriers:

- Requires ISO-certified facilities with controlled environments
- 78% of Indian districts lack NGS-capable centers vs. 32% without ddPCR access

A 2025 meta-analysis noted that ddPCR adoption increased NIPT availability by 300% in low/middle-income countries compared to NGS [50].

Clinical Applications and Limitations

When to Choose ddPCR:

- High-prevalence trisomies in resource-limited settings
- Rapid confirmation of ultrasound-identified anomalies
- Quantifying FF in obese patients or early gestation1

NGS Preferred For:

- Genome-wide microdeletion/microduplication screening
- Multiple gestation pregnancies requiring complex zygosity analysis
- Research studies investigating novel fetal biomarkers

Future Directions

Hybrid models using NGS for primary screening and ddPCR for confirmatory testing could optimize cost-effectiveness. Emerging solutions include:

- AI-enhanced ddPCR: Machine learning algorithms improving low-FF sensitivity
- Nanofluidic chips: Enabling 12-plex ddPCR assays for $50/test

- Methylation-ddPCR: Combining epigenetic analysis with droplet partitioning

ddPCR democratizes NIPT access through rapid, affordable testing but trails NGS in comprehensive genomic analysis. For targeted aneuploidy detection in public health programs, ddPCR's 3:1 cost advantage and simplified workflow make it transformative. However, NGS remains indispensable for complex diagnoses, underscoring the need for context-specific implementation strategies.

Innovations in Fetal Fraction Estimation

- Methylation-Based Fetal Fraction Estimation Models
- SNP-, Sex-, and Ploidy-Independence in Fetal Fraction Analysis

Innovations in Fetal Fraction Estimation: Methylation-Based Models and SNP-, Sex-, and Ploidy-Independent Approaches

Non-invasive prenatal testing (NIPT) has revolutionized prenatal care by providing a safer alternative to invasive diagnostic procedures like amniocentesis. Central to NIPT's accuracy is the correct estimation of the fetal fraction, the percentage of cell-free fetal DNA (cffDNA) in the maternal bloodstream [52]. Low or inaccurately measured fetal fractions are a major cause of false-negative and test failure cases [53].

Historically, fetal fraction estimation relied on fetal-specific genetic markers such as Y-chromosome sequences for male fetuses or differential SNP alleles. However, these methods have limitations, particularly for female fetuses and pregnancies complicated by aneuploidy. Innovations such as methylation-based fetal fraction models and SNP-, sex-, and ploidy-independent approaches have been developed to overcome these challenges [54].

Traditional Methods of Fetal Fraction Estimation

SNP-Based Approaches-

SNP-based methods involve analyzing allelic differences between maternal and fetal DNA [55]. By identifying paternal-specific SNPs absent in the maternal genome, fetal fraction can be calculated. However, this approach is constrained by the availability of informative SNPs and is sensitive to population-specific genetic variations [56].

Y-Chromosome Quantification-

Quantitative PCR or sequencing targeting Y-chromosome sequences has been widely used for estimating fetal fraction in pregnancies with male fetuses [57]. While highly effective for male fetuses, it fails entirely for female fetuses, making it unsuitable for universal application.

Fragment Size Analysis- Fetal cfDNA fragments are generally shorter (~143 bp) than maternal cfDNA fragments (~166 bp) [58]. Methods exploiting these size differences provide an indirect estimation of fetal fraction, but the significant overlap in size distributions limits precision and reliability [59].

Innovations in Fetal Fraction Estimation - The demand for more universal, accurate, and reliable fetal fraction estimation methods has driven research into alternative strategies independent of fetal genetic specifics.

1) Methylation-Based Fetal Fraction Estimation Models

Biological Rationale-

Placental tissue, which contributes the majority of cffDNA, exhibits distinct DNA methylation patterns compared to maternal somatic tissues. [60]. These differences enable discrimination between fetal and maternal cfDNA in maternal plasma.

Methodologies-

Methylation-Sensitive Restriction Enzyme Assays-

Early approaches used methylation-sensitive restriction enzymes to selectively digest maternal cfDNA, enriching for methylated fetal DNA [61]. While effective, these methods required prior knowledge of methylation patterns and could be biased by incomplete digestion.

Bisulfate Conversion and Sequencing-

Bisulfate treatment converts unmethylated cytosines to uracil, allowing direct analysis of methylation patterns via sequencing. Studies have demonstrated the feasibility of using methylation signatures to estimate fetal fraction across various gestational ages accurately. [62].

Advantages and Limitations

- Methylation-based models offer several advantages:
- Universality: Applicable to all pregnancies, regardless of fetal sex.
- Stability: Methylation signatures are consistent and less affected by genetic diversity.

However, technical challenges such as DNA degradation during bisulfate conversion and the need for high sequencing depth remain. [63].

2) SNP-, Sex-, and Ploidy-Independent Methods

- Nucleosome Footprint Analysis

Cell-free DNA retains nucleosome footprints from its tissue of origin. Differences in nucleosome positioning between placental and maternal cells create distinct fragmentation patterns that can be analyzed to infer fetal fraction. [64].

- Machine Learning Models-

Recent approaches integrate multiple cfDNA features, such as fragment size, GC content, methylation levels, and nucleosome patterns, into machine learning models to predict fetal fraction. [65]. These models can generalize across populations and clinical conditions without relying on fetal genotype.

- Comparative Analysis: Compared to traditional methods, SNP-, sex-, and ploidy-independent models offer:

Broad applicability: Including aneuploid pregnancies and female fetuses.

Higher accuracy, especially at low fetal fractions.

Reduced sample rejection rates: Enhancing clinical reliability [66].

Validation and Clinical Impact-

Validation Studies

Studies such as that by Xiang et al. (2020) have shown that methylation-based and SNP-independent models provide equivalent or superior accuracy compared to traditional methods, especially in early gestation and complicated pregnancies.

For example, a large cohort analysis demonstrated that methylation-based fetal fraction estimation yielded more consistent results in samples with low fetal DNA content than SNP-based estimation. [67].

Clinical Applications

Accurate fetal fraction estimation impacts:

Diagnostic accuracy: Reducing false negatives and false positives.

Lower test failure rates: Especially in early gestation and obese patients [53].

Broadening clinical access: Enabling equitable testing across diverse populations.

Future Directions

1)Single-Molecule Sequencing Integration

Nanopore and other single-molecule sequencing technologies, capable of directly detecting methylation marks without PCR amplification, could enhance fetal fraction estimation with greater accuracy and lower costs [68].

2)Universal NIPT

The development of universal NIPT platforms independent of fetal sex, ethnicity, and genetic variations will depend heavily on further refinement of methylation-based and machine learning-integrated fetal fraction estimation strategies [69].

3)Ethical Considerations

As NIPT technologies grow increasingly sensitive, ethical concerns around incidental findings, privacy, and informed consent will become even more critical [70].

Recent Advances in ddPCR for NIPT

- High-Multiplex Assays for Rapid Screening
- Integration with Chip-Based Platforms for Enhanced Throughput
- Emerging Applications: Rare Aneuploidies and Microdeletions

Recent Advances in Droplet Digital PCR for Non-Invasive Prenatal Testing (NIPT)

Non-invasive prenatal testing (NIPT) assesses fetal chromosomal abnormalities through analysis of cffDNA present in maternal plasma, minimizing the risks associated with invasive procedures like amniocentesis. Traditionally, next-generation sequencing (NGS) has dominated NIPT; however, droplet digital PCR (ddPCR) is gaining attention for its precision, cost-effectiveness, and rapid turnaround [71].

Droplet digital PCR partitions a DNA sample into thousands of nanoliter-sized droplets, allowing absolute quantification without the need for standard curves [10]. Its application in NIPT offers promising improvements in sensitivity and specificity, especially for the detection of low-abundance targets.

Fundamentals of ddPCR in NIPT

- Principle of ddPCR

In ddPCR, a PCR reaction mixture is divided into thousands of individual droplets before amplification. Following PCR, each droplet is read individually to determine the presence (positive) or absence (negative) of target sequences, enabling absolute quantification of nucleic acids [10].

- Advantages Over qPCR and NGS

Compared to qPCR, ddPCR is less affected by PCR efficiency variations and enables more precise quantification [72]. Against NGS, ddPCR offers: Faster results, Lower costs, Simplified workflows, High sensitivity for specific targets. However, challenges like multiplexing limitations and low throughput compared to NGS remain.

High-Multiplex Assays for Rapid Screening

- Need for High Multiplexing in NIPT

A significant limitation of early ddPCR-based NIPT assays was the detection of only a few chromosomal targets at once. However, clinical applications demand broader panels capable of screening for multiple conditions simultaneously.

- Multiplexing Strategies

Recent technological innovations have enabled high-multiplex ddPCR assays:

Color-coding fluorescent probes: Using multiple fluorophores and varying signal intensities allows simultaneous detection of multiple targets within a single droplet set [73].Amplitude-based multiplexing: Differentiating targets based on varying fluorescence intensities within the same color channel [74].For instance, Persoon et al. (2020) developed a ddPCR assay that simultaneously detects trisomies 13, 18, and 21 in a single reaction, reducing the need for sequential testing.

Advantages

High-multiplex ddPCR assays provide:

Rapid diagnosis within a few hours.

Reduced costs through fewer reagents and processing steps.

Broader clinical coverage without increasing sample input.

Integration with Chip-Based Platforms for Enhanced Throughput

The Challenge of Low Throughput-

Traditional droplet generation limits the speed at which large numbers of samples can be processed, making ddPCR less attractive for high-volume clinical laboratories.

Chip-Based Droplet Digital PCR-

Chip-based ddPCR platforms, such as Bio-Rad's AutoDG and Stilla Technologies' Naica system, use microfluidic chips to automate droplet generation and reading, greatly enhancing throughput [75]. For example, Stilla's Crystal Digital PCR technology partitions samples into thousands of

droplets on a single chip, enabling parallel processing of multiple samples [76]. Automated sample preparation and parallel droplet generation reduce human error and labor.

Clinical Impact

Increased scalability: Suitable for population-wide screening programs.

Faster turnaround times: Results available within a day.

Greater standardization: Automation reduces variability between runs.

Integrating ddPCR with chip-based platforms bridges the gap between small-scale research and large-scale clinical deployment.

Emerging Applications: Rare Aneuploidies and Microdeletions

Beyond Common Trisomies-

While traditional NIPT focuses on trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome), there is growing demand for detecting rarer chromosomal anomalies.

ddPCR for Rare Aneuploidies-

Researchers have developed ddPCR assays for conditions like:

Monosomy X (Turner syndrome) [77].

Trisomy 16 and Trisomy 22, which often result in miscarriage but are occasionally viable [78].

Because of ddPCR's high sensitivity, it is particularly well-suited for detecting these rare events, even when fetal fraction is low.

Detection of Microdeletion-

Microdeletions, such as 22q11.2 deletion syndrome (DiGeorge syndrome), present unique challenges due to their small size (typically <3 Mb).

Recent studies have demonstrated:

ddPCR assays capable of detecting 22q11.2 deletions with high sensitivity and specificity [79].

Simultaneous detection of multiple microdeletions using multiplexed probes targeting specific chromosomal regions [80].

This enables earlier and more accurate prenatal diagnosis of syndromes that might otherwise go undetected in routine NIPT.

Challenges and Limitations

Despite its advantages, ddPCR faces hurdles:

Limited multiplexing: Even advanced systems cannot yet match NGS's broad genomic coverage.

Cost per target: While cheaper than NGS for a few targets, high-multiplex ddPCR becomes costly for very large panels.

Technical complexity: Requires rigorous assay design and optimization.

Addressing these limitations will be critical for expanding ddPCR's role in routine clinical NIPT.

Future Directions

- Ultra-High Multiplexing

Emerging technologies such as combinatorial probe barcoding and spectral flow cytometry-like droplet reading could push ddPCR multiplexing to new heights [81].

- Portable ddPCR Devices

Microfluidic advances are driving the development of point-of-care ddPCR platforms capable of delivering NIPT results in decentralized settings, expanding access worldwide [82].

- Integration with AI

Machine learning models trained on droplet fluorescence patterns and concentration data could automate interpretation, enhancing accuracy and reducing manual workload [83].

Future Scope

- Expansion to Detect Microdeletions and Rare Genetic Disorders
- Automation and High Throughput Platforms

- Global Implementation in Low-Resource Settings

Non-invasive prenatal testing (NIPT) leveraging cell-free fetal DNA (cffDNA) has become a routine screening tool for common chromosomal aneuploidies. While next-generation sequencing (NGS) has traditionally dominated this field, droplet digital PCR (ddPCR) is gaining traction due to its precision, lower cost, faster turnaround, and ease of standardization (Hindson et al., 2011; Zimmermann et al., 2012).

The future of ddPCR-based NIPT hinges on extending its diagnostic capabilities beyond common aneuploidies, enhancing automation to meet growing demand, and democratizing access worldwide. This literature review highlights the latest advancements and foreseeable trends shaping ddPCR's future in prenatal diagnostics.

Expansion to Detect Microdeletions and Rare Genetic Disorders-

Limitations of Current ddPCR-based NIPT

Historically, ddPCR-based NIPT has been limited to detecting common trisomies (trisomy 21, 18, and 13) due to the relatively large chromosomal abnormalities involved. Detecting smaller genomic alterations, like microdeletions, poses greater challenges because of the subtle differences in DNA copy number (Srinivasan et al., 2013).

Advances in Microdeletion Detection

Recent innovations have expanded ddPCR capabilities for detecting sub-chromosomal anomalies:

- 22q11.2 Deletion Syndrome (DiGeorge syndrome): Early studies using targeted ddPCR assays demonstrated high sensitivity and specificity in detecting 22q11.2 deletions (Shin et al., 2020).
- Prader-Willi and Angelman Syndromes (15q11-q13 deletions): ddPCR strategies targeting known breakpoint regions have shown promise in accurately identifying these deletions prenatally (Yu et al., 2019).

Multiplexing several ddPCR assays enables simultaneous detection of multiple microdeletions within a single reaction, enhancing clinical utility (Sanders et al., 2019).

Rare Genetic Disorder Screening

Beyond structural anomalies, ddPCR is being adapted for rare single-gene disorders:

- β-thalassemia: ddPCR can distinguish between mutant and wild-type alleles in maternal plasma (Vossaert et al., 2018).
- Cystic fibrosis: Specific mutations like ΔF508 can be detected through highly sensitive ddPCR assays (Chitty et al., 2015).

This ability to target discrete single-nucleotide changes opens the door for broader genetic disease screening during pregnancy.

Automation and High Throughput Platforms -

Bottlenecks in Manual ddPCR Workflows-

Manual ddPCR processes are labor-intensive, requiring careful sample handling, droplet generation, thermal cycling, and droplet reading. Such workflows are impractical for large-scale clinical applications.

Emergence of Automated ddPCR Systems -

Innovations are driving automation:

- AutoDG by Bio-Rad: Automates droplet generation, reducing hands-on time and variability (Oudejans, 2020).
- Stilla Technologies' Naica System: Integrates droplet generation, thermal cycling, and droplet reading into a single platform.

These platforms:

- Enhance reproducibility.
- Shorten turnaround times.
- Allow parallel processing of multiple samples.

Benefits of Automation

Automation improves:

- Sample-to-answer workflows, minimizing contamination.
- Standardization across laboratories, crucial for regulatory approvals.
- Scalability, enabling national or regional NIPT programs.

Moreover, real-time cloud-based data analysis, already emerging in some platforms, promises to make remote diagnostic decision-making feasible.

Global Implementation in Low-Resource Settings

The Inequity in Prenatal Screening Access-

Currently, NIPT is predominantly available in high-income countries. Cost, infrastructure requirements, and trained personnel limitations hinder access in low- and middle-income countries (LMICs).

ddPCR as an Affordable Alternative

Compared to NGS:

- **Lower equipment costs**: ddPCR machines are significantly cheaper than high-throughput sequencers.
- **Simpler workflows**: Reduced bioinformatics needs.
- **Reduced reagent costs**: Targeted assays require fewer reagents.

Hence, ddPCR is poised as a more realistic technology for LMICs.

Innovations Supporting Global Reach

Several strategies aim to adapt ddPCR for low-resource settings:

- Portable ddPCR Devices: Handheld or suitcase-sized ddPCR machines under development could bring NIPT to rural clinics (Liang et al., 2020).
- Lyophilized Reagents: Stable at ambient temperatures, eliminating cold chain logistics.

- Battery-powered Thermal Cyclers: Enabling use in regions with unreliable electricity supplies.

Additionally, pooled sample testing models are being evaluated to reduce per-test costs further (Turbett et al., 2020).

Capacity Building

Training local healthcare professionals and establishing quality control frameworks are vital for sustainable NIPT program expansion in LMICs (Stephenson et al., 2018).

Challenges and Considerations

Despite its promise, several hurdles exist:

- Assay Design Complexity: Microdeletions and rare mutations demand highly specific and sensitive probe designs.
- Multiplexing Limits: Although improving, ddPCR still faces challenges scaling to genome-wide screening levels.
- Regulatory and Ethical Issues: Widespread adoption, especially for expanded panels, raises ethical concerns about incidental findings (Botkin et al., 2019).
- Data Interpretation: Requires careful clinical context consideration to avoid overdiagnosis.

Addressing these issues will be crucial for ddPCR's continued growth.

Future Prospects

Next-Generation ddPCR Technologies

Emerging innovations may soon enable:

- Ultra multiplexed ddPCR: Detecting dozens of targets simultaneously using sophisticated probe designs and AI-powered droplet analysis (Kleftogiannis et al., 2020).
- Integration with CRISPR-based detection systems: Enhancing mutation detection specificity (Chen et al., 2021).

Personalized NIPT

Future ddPCR-based NIPT could be personalized based on parental carrier status, screening for only relevant conditions in a pregnancy-specific manner (Wright et al., 2019).

Combining ddPCR and NGS

Hybrid platforms that use ddPCR for initial rapid screening and NGS for confirmatory, broad genomic analysis may provide the best of both worlds, balancing speed, cost, and coverage.

Droplet digital PCR (ddPCR) represents a transformative technology for the future of non-invasive prenatal testing. Expanding its capabilities to detect microdeletions and rare genetic disorders, leveraging automation for clinical scalability, and making it accessible globally are essential next steps. As technological, ethical, and logistical challenges are addressed, ddPCR is well-positioned to redefine prenatal care across diverse populations and resource settings.

CHAPTER 3

MATERIALS AND METHODOLOGIES

DNA EXTRACTION FROM PLASMA-

Step 1: Blood Collection and Initial Plasma Separation

Procedure:

- Sample Collection: Draw 8 mL of whole blood into a specialized Cell-Free DNA BCT® tube to stabilize nucleic acids.
- Visual Cue: The tube appears filled with blood, with an outer label indicating the sample ID.
- Initial Centrifugation: Spin the blood sample at 1,600 × g for 10 minutes at 4°C.
- Top layer: Plasma (clear, straw-colored).
- Bottom layer: Buffy coat (white layer of centrilobular white blood cells).

Key Point: Do not disturb the buffy coat; carefully transfer the transparent plasma to avoid contamination.

Step 2: Plasma Transfer (Isolate plasma for further high-speed centrifugation)

Procedure:

- Using a pipette, gently aspirate the plasma layer without disturbing the buffy coat.
- Transfer to a sterile, labeled 2-mL centrifuge tube.

Step 3: High-Quality Plasma Clarification (Remove residual cell debris and apoptotic bodies that may contaminate cfDNA.)

Procedure:

- Centrifuge the plasma at 16,000 × g for 10 minutes at 4°C.

Key Point: Aspirate the supernatant carefully without disturbing the pellet to retain pure cfDNA.

Step 4: Plasma Storage or Preparation for Extraction (Preserve plasma integrity for downstream extraction.)

Procedure:

- Transfer the clarified plasma into a new sterile, labeled storage tube.
- Optional: Store at -80°C if not processing immediately.

Step 5: Thawing and Preprocessing (Prepare plasma for DNA extraction.)

Procedure:

- Thaw plasma at 4°C or room temperature.
- Mix gently to ensure homogeneity.
- Optionally, centrifuge at 3,000 × g for 1 minute to remove any residual debris.

Step 6: Preparation of Reagents and Equipment (Set up necessary reagents and equipment.)

Key Reagents:

- Buffer AL (lysis buffer)
- Ethanol (96-100%)
- Carrier RNA
- Proteinase K
- Buffers AW1 and AW2
- Buffer AE for elution

Step 7: Volume Dispensation and Lysis (Lyse plasma to release cfDNA.)

Procedure:

- Pipette 334 µL of plasma into a clean 1.5 mL tube.
- Add 334 µL of Buffer AL.
- Add 334 µL of ethanol, mix thoroughly (by pipetting or gentle vortex).

Incubation:

- Place the tube in a heat block or incubator at 56°C for 10 minutes, ensuring intermittent tap or vortexing every 2 minutes to facilitate thorough lysis.

Step 8: Binding cfDNA to the Spin Column (Capture released cfDNA onto silica membrane.)

Procedure:

- Transfer the entire lysate to a QIAamp Mini spin column mounted on a collection tube.
- Centrifuge at 8,000 rpm (~6,000 × g) for 1 minute.
- Discard the filtrate.
- Repeat transfer and centrifugation if volume remains, ensuring all lysate passes through the membrane.

Step 9: Wash and Purify (Remove contaminants via successive washes.)

Procedure:

- Wash 1:
- Add 500 µL Buffer AW1.
- Centrifuge at 8,000 rpm for 1 minute.
- Discard flow-through.
- Wash 2:
- Add 500 µL Buffer AW2.
- Centrifuge at 14,000 rpm (~20,000 × g) for 3 minutes.
- Discard flow-through.
- Additional Spin:
- To eliminate residual ethanol, perform a final centrifugation at maximum speed (~14,000 rpm) for 1 minute.

Step 10: Elution of cfDNA (Retrieve purified cfDNA from silica membrane.)

Procedure:

- Place the spin column into a new, clean 1.5 mL collection tube.
- Add 50 µL of pre-warmed (60°C) Buffer AE directly onto the membrane.
- Incubate at room temperature for 30 minutes (can be shortened to 5 minutes for acceptable yield).
- Centrifuge at 10,000 rpm for 1 minute to elute cfDNA into the collection tube.
- Discard the spin column.

Step 11: Quantification of Extracted DNA (Determine the concentration of purified cfDNA.)

Procedure:

- Prepare the Qubit dsDNA HS reagent working solution (1:200 dilution).
- Mix 2 µL of the eluate with 198 µL of dye reagent.
- Incubate for at least 2 minutes.
- Measure fluorescence using the Qubit Fluorometer.
- The software automatically calculates the DNA concentration and allows for the correction of dilution factors to obtain the original sample concentration.

Step 12: Storage of Purified cfDNA (Preserve DNA integrity for future analyses.)

Procedure:

- Store the eluted cfDNA at -80°C.
- Avoid multiple freeze-thaw cycles to maintain sample quality.



FIGURE 1: Overview of DNA Purification from Plasma.

Yourgene cfDNA Library Preparation Kit

Principle-The Yourgene cfDNA Library Preparation Kit operates on a series of enzymatic reactions designed to convert extracted cell-free DNA (cfDNA) into sequencing-ready libraries for next-generation sequencing (NGS). The process begins with DNA end repair, where enzymes produce blunt-ended DNA fragments with phosphorylated 5' termini, facilitating efficient adaptor ligation. During the barcoded adaptor ligation step, unique barcode-containing oligonucleotides are ligated to the repaired DNA fragments using DNA ligase, enabling sample multiplexing, while a DNA polymerase repairs nicks between the DNA and adaptors. Following ligation, a magnetic bead-based cleanup removes excess reagents and unligated adaptors, enriching for correctly ligated DNA molecules. The final step involves PCR amplification of the purified library using high-fidelity DNA polymerase and specific primers, which increases the library quantity for sequencing and incorporates necessary sequencing motifs. Throughout the protocol, magnetic bead purification and enzyme-mediated reactions ensure high-fidelity, efficient library preparation tailored for cfDNA, supporting accurate and high-throughput sequencing analyses.



FIGURE 2: End Repair



FIGURE 3: Adaptor Ligation



FIGURE 4: PCR Amplification

Reagents and Kits:

- Yourgene cfDNA Library Preparation Kit (Rev 1, March 2021): Designed for preparing cell-free DNA (cfDNA) samples for whole genome next-generation sequencing in research applications. The kit contains all necessary reagents and enzymes for library construction as specified in the user guide.
- PCR Primer Mix I and PCR Master Mix I: Used during the library preparation PCR amplification process, as detailed in the protocol.
- Nuclease-free water: Employed for resuspending bead pellets during purification steps.
- 80% Ethanol: Utilized for washing beads during the cleanup procedure.

Equipment Required:

- Centrifuge: Spectrafuge™ Mini Centrifuge with 0.2 mL rotor (Fisher Scientific) or equivalent capable of pulse spinning and quick spin-down steps.
- Magnetic rack/plate: Fisher Scientific/Alpaqua magnetic rack/plate (item numbers 10723874/A001322).
- Thermal cycler: Must be compatible with 0.2 mL tubes and capable of adjustable ramp rates up to 2.5°C/sec, facilitating end repair, ligation, and amplification steps.
- Plate spinner: Plate Spinner for proper mixing and bead resuspension.
- Vortex mixer: For thorough mixing of reagents and samples.
- Pipettes: Various, including 20-200 µL and 2-20 µL

Personal Protective Equipment (PPE):

- Laboratory coat, disposable gloves, protective safety glasses to ensure safety when handling reagents and performing procedures.
- Appropriate PPE must be worn at all times during operations involving chemicals or biological samples.

Storage and Handling of Reagents:

- Store kit reagents at refrigerated temperatures (1.5 mL plates at 2-8°C) or frozen as specified.
- Upon receipt, reagents stored incorrectly may have reduced stability:
- Plates 1 and 3 should be refrigerated; stability reduced to 11 days if stored at fridge temperature.
- Plate 2 should be stored at -20°C; stability reduced to 14 days if stored at freezer temperature.
- If stored at ambient temperature, stability is reduced to 7 days.
- Thaw frozen libraries for 30 minutes prior to use and ensure Plate 2 is also removed from storage 30 minutes before proceeding.

Sample Preparation and Library Construction:

- Starting Material: Extracted cell-free DNA (cfDNA) samples prepared according to standard protocols.
- End Repair: Combine extracted DNA with enzyme mixes to produce blunt-ended fragments with phosphorylated 5' ends. Incubate as per the protocol.
- Adaptor Ligation: Ligate barcoded adaptors to the prepared DNA fragments using ligase and DNA polymerase enzymes. Incubate at the specified temperature and duration.
- Post-ligation cleanup: Use magnetic bead-based purification with 80% ethanol washes:
- Mix 50 µL of library sample with 50 µL of beads, incubate for 5 minutes at room temperature, then perform magnetic separation.
- Wash twice with 80% ethanol, then air dry for 30 seconds.
- Re-suspend bead pellet in 30 µL nuclease-free water.
- Library Amplification: Transfer supernatant for PCR amplification using specific primers and master mixes:
- Prepare PCR reactions by adding 24 µL of the cleaned-up library, along with 1 µL of PCR Primer Mix I (positions 10A/B) and 25 µL of PCR Master Mix I (columns 11 and 12).

- PCR cycling conditions should follow the manufacturer's instructions to avoid amplification bias.
- Post-PCR Cleanup: Repeat bead purification steps as described, including ethanol washes and air drying.
- Quantification: Quantify the purified libraries using microfluidic or fluorometric platforms compatible with DNA analysis, ensuring the concentration falls within the detection range of the platform used.

Quality Control and Normalization:

- Libraries are to be checked for concentration and fragment size distribution.
- Normalization and multiplexing are performed prior to size selection, if necessary, with up to 48 libraries pooled per sequencing run.

Safety and Precautions:

- Handle all chemicals and biological materials following safety guidelines, always using PPE.
- Refer to the relevant Material Safety Data Sheets (MSDSs) for specific reagents.
- Operate equipment according to manufacturer instructions and institutional safety procedures.

This detailed methodology ensures accurate and reproducible preparation of cfDNA libraries for subsequent sequencing analysis.

Materials and Methods (Size Selection using Yourgene cfDNA Quant select)

Principle- The test procedure is based on the principles of fluorescence-based DNA quantification and size selection, carried out using the Yourgene QS 250 instrument. Initially, DNA samples and standards are mixed with a fluorescent reagent that allows for sensitive detection of DNA through excitation and emission of specific wavelengths. The mixture is loaded into a black 384-well plate, and the instrument images each well under consistent lighting conditions to measure fluorescence units, which are automatically converted into DNA mass (ng). For size selection, the DNA-containing mixture is combined with Loading Buffer that contains fluorescent markers and SYBR® Gold, enabling visualization of DNA fragments and markers with different colors. The sample is then passed through a 12-channel 3% agarose gel cassette, where the SSR software tracks

fragment migration to isolate a specific size range of cfDNA. Subsequently, the selected DNA is concentrated using magnetic beads; impurities are washed away, and the purified DNA is eluted with nuclease-free water for further analysis. This automation ensures precise size selection and quantification essential for downstream applications.

Reagents and Equipment

- Utilized the Yourgene cfDNA Quant select Kit, suitable for size selection, quantification, and concentration assessment of cfDNA.
- Kit components included:
- 2 x black 384-well plates
- 8 x foil seals
- Loading Buffer
- 1 x 28.5 µL 12-channel 3% agarose gel cassette
- 8 x adhesive seals for the cassette
- 4 x 8-well strip tubes containing Concentration Reagents (130 µL per well)
- Storage at -25°C to -15°C for the Loading Buffer
- Additional required materials not provided:
- Freezer, refrigerator
- 50 mL tubes
- Vortex mixer
- Plate centrifuge and microcentrifuges suitable for 0.2 mL and 1.5/2 mL tubes
- Low DNA-binding capacity microcentrifuge tubes
- Magnetic rack
- Nuclease-free water

- Molecular biology-grade ethanol (96-100%), avoiding denatured alcohol containing methanol or methylethylketone
- Pipette tips:
- Use DNase, RNase, and DNA-free tips with filters
- Equipment calibration:
- Perform regularly following manufacturer or in-house guidelines

Sample Preparation and Reagent Handling

- Equilibrate all kit components at ambient temperature (15-25°C)
- Allow Loading Buffer to equilibrate for at least 20 minutes, protected from light
- Equilibrate the agarose gel cassette for at least 60 minutes at ambient temperature
- Prepare cfDNA samples by diluting extracted DNA with appropriate buffers
- Quantify DNA concentration using fluorometric methods to ensure accurate input
- Prepare standards by diluting known DNA concentrations (e.g., 10 ng/µL) and include no-template controls
- Document all solution preparations and sample details in the Traceability Worksheet

Size Selection and Quantification Protocol

- Mix 6 µL of sample or standard with 54 µL of Loading Buffer in each well
- Pipette thoroughly to ensure homogeneity, avoiding bubbles
- Load the prepared plate into the Yourgene QS250 instrument
- Assign run names and highlight wells corresponding to samples and standards within the software
- Select the "Quant only" option for fluorescence measurement
- Record fluorescence readings and calculate DNA concentrations automatically

- Initiate size selection by selecting the relevant wells and starting the protocol
- Insert the gel cassette with the sample into the instrument for size separation
- After completion, carefully remove size-selected samples for downstream processing

Post-Processing and Data Recording

- Manually record measurement data, including fluorescence units and DNA quantities, into the Traceability Worksheet
- Document reagent batch numbers, sample IDs, and run details for traceability and reproducibility

Safety Considerations

- Wear appropriate PPE: laboratory coat, gloves, safety glasses
- Handle magnetic racks with caution, especially with individuals who have pacemakers
- Follow proper waste disposal procedures
- Regularly calibrate and maintain equipment
- Store reagents under recommended conditions and verify their stability before use

Digital Droplet PCR

System and Reagents: The experiments were conducted using the QuantStudio™ Absolute Q™ Digital PCR System. Reagents employed included the Absolute Q™ DNA Digital PCR Master Mix (5X), Absolute Q™ Starter Assay (20X), and CEPH genomic DNA (gDNA) control at a concentration of 50 ng/µL. Additional consumables comprised P10 or P20 pipettes with filter tips, a vortex mixer, microcentrifuge tubes, and a benchtop microcentrifuge. Nuclease-free water was used throughout the procedure. All reagents and consumables were handled following standard laboratory safety protocols.

Preparation of Reaction Mixture

- Thaw and equilibrate all reagents (Master Mix, Starter Assay, CEPH gDNA control) to room temperature prior to use.

- Protect reagents from light throughout the procedure.
- Pulse-vortex the Absolute Q™ DNA Digital PCR Master Mix (5X) and Absolute Q™ Starter Assay (20X) at high speed for 10 seconds.
- Prepare the CEPH gDNA control by diluting 4 µL of the 50 ng/µL stock to 10 ng/µL with nuclease-free water.
- Calculate and prepare the reaction mix for each sample, including:
- 2 µL of Master Mix
- 0.5 µL of Starter Assay
- The appropriate volume of diluted CEPH gDNA control
- Nuclease-free water to reach the final volume, with an overage of 10%
- Mix the reaction components gently by pipetting 10-20 times or vortexing for 3-5 seconds.
- Centrifuge the mixture briefly at 10,000 × g for 1 minute.

Use the prepared reaction mix within one hour of preparation to ensure optimal results.

Loading the MAP Plate: Prior to sample loading, the MAP plate was removed from its packaging using aseptic techniques and handled by its frame to prevent contamination. Approximately 9 µL of the reaction mixture was carefully transferred into each well of the MAP plate using a P10 or P20 pipette with filter tips, ensuring the tip was inserted at a 45° angle to minimize bubble formation and contact with the well bottom. Subsequently, 15 µL of Absolute Q™ Isolation Buffer was added to each well, carefully overlaying the reagent mixture, minimizing mixing and bubble formation. The plate was then sealed with gasket strips and centrifuged briefly to ensure proper settling and bubble removal.

Experimental Procedure and Data Acquisition

The prepared MAP plate was loaded into the QuantStudio™ Absolute Q™ Digital PCR System for thermal cycling according to the system's specifications. The system's software monitored the run status, with the instrument lights pulsing blue during processing and becoming steady blue upon completion. Data was automatically populated in the ANALYSIS tab during and after the run.

FIGURE 5: Applied Biosystems Quant Studio Absolute Q Digital PCR System



FIGURE 6: MAP plate without Plate gasket strips





FIGURE 7: 1) Microfluidic channel to the Micro reaction chamber array

2) The reagent remains in the well until the instrument pushes it into the micro reaction chamber array during the run.



Figure 8: Isolation buffer sits on the top of the reagent, preventing contamination and evaporation

Figure 9: Place the MAP plate gasket strips firmly in place

CHAPTER 4

RESULTS & DISCUSSIONS

A droplet digital PCR (ddPCR) methodology offers a highly sensitive, specific, yet practical solution for non-invasive prenatal detection of fetal genetic abnormalities. Compared to conventional Next Generation Sequencing (NGS)-based non-invasive prenatal testing (NIPT), ddPCR matches and in certain targeted contexts can exceed NGS in diagnostic performance and provides operational advantages that are increasingly relevant to clinical practice.

Analytical Performance: Specificity and Sensitivity

For conditions such as trisomy 21, meta-analytic evaluations demonstrate that ddPCR achieves a pooled sensitivity of 98% (95% CI: 94-100%) and specificity of 99% (95% CI: 99-100%), values that closely parallel, and at times surpass, those of established NGS procedures. In quantitative measurement of fetal DNA fractions and detecting chromosomal aneuploidies, studies have shown ddPCR to have strong concordance with NGS results and exhibit reduced technical variability across a range of fetal DNA percentages. This high reliability extends even to low-fetal fraction scenarios, traditionally challenging for other methods.

Operational and Clinical Advantages

- Expedited Turnaround: Unlike NGS, which typically demands a minimum of three days from sample to result, ddPCR workflows can be completed in approximately 90 minutes. This rapid diagnostics window is vital in time-sensitive clinical settings or emergency interventions.
- Sample Efficiency: ddPCR maintains robust sensitivity with small volumes or low-fraction cell-free fetal DNA conditions that can hamper the performance of NGS, especially in early gestation or in individuals with high body mass index.
- Cost-Effectiveness: The per-test cost of ddPCR is significantly lower (reported at approximately $110/test) versus NGS (around $570/test), largely due to the reduced need for labor, consumables, and computational infrastructure.

- Workflow Simplicity: Relative to NGS, ddPCR features a streamlined, user-friendly protocol with fewer steps and less technological complexity, facilitating implementation in various laboratory environments, including resource-limited settings.

Limitations and Considerations

- Detection Scope: ddPCR is ideally suited for identifying known, specific genetic abnormalities such as common aneuploidies or monogenic disorders, but does not offer the comprehensive, genome-wide screening capacity characteristic of NGS.
- Occasional False Results: Despite high sensitivity and specificity, rare false positives or negatives can occur with ddPCR. This underscores the importance of careful assay validation and confirmatory testing when results are ambiguous.
- Complex and Unexpected Cases: For detecting intricate genetic conditions, including mosaicism or previously uncharacterized mutations, NGS remains the superior approach owing to its broad sequencing capability and capacity for comprehensive genomic profiling.

Interpretation of Throughput and Clinical Applicability

While NGS platforms can accommodate broad panels and simultaneous multi-locus analysis in a single run, the clinical utility of ddPCR lies in its ability to quickly and accurately resolve targeted diagnostic questions with just a few runs. This paradigm is well-suited for the most common clinical prenatal applications, where the abnormalities of interest are predetermined. Reducing run time, technical burden, and cost positions ddPCR as a particularly viable choice in cases where rapid, targeted results are prioritized over exploratory genomic screening.

DdPCR presents a rapid, accurate, and economically favorable alternative to traditional NGS for targeted non-invasive prenatal genetic analysis. The decision between ddPCR and NGS should thus be guided by the specific clinical scenario, using ddPCR where focused, high-confidence detection of known abnormalities is sufficient, and reserving NGS for situations necessitating comprehensive genomic interrogation

CHAPTER 5

CONCLUSION

In summary, the adoption of droplet digital PCR (ddPCR) in non-invasive prenatal testing marks a significant advancement in detecting fetal genetic abnormalities. The body of evidence from the present analysis confirms that ddPCR consistently achieves high sensitivity and specificity on par with, and in targeted contexts sometimes exceeding, traditional Next Generation Sequencing (NGS) methodologies. The primary strengths of ddPCR lie in its rapid turnaround time, cost-effectiveness, and operational simplicity, delivering reliable results within approximately 90 minutes and requiring minimal resources.

These attributes make ddPCR especially valuable in clinical settings where swift clinical decision-making is critical or in regions with limited access to complex sequencing infrastructure. The streamlined workflow of ddPCR and its robustness in handling samples with low fetal DNA fraction position this technology as a practical and accessible alternative to standard NGS for targeted prenatal testing.

Nevertheless, the scope of ddPCR is best suited for known genetic targets such as common aneuploidies and select monogenic disorders. At the same time, comprehensive genome-wide screening and detecting rare or complex variants remain the domain of NGS. Thus, the choice between ddPCR and NGS should be guided by the specific clinical objectives: ddPCR excels for focused, high-confidence applications, whereas NGS remains indispensable for broader diagnostic inquiries.

In conclusion, ddPCR represents a transformative tool for non-invasive prenatal diagnostics, widening access to safe, fast, and accurate genetic screening. Future directions should focus on developing multiplex ddPCR assays and further multi-center validation studies to reinforce its role as a frontline technology in prenatal genetic medicine.

CHAPTER 6

REFERENCES

[1] M. Allyse *et al.*, "Non-invasive prenatal testing: a review of international implementation and challenges," *International journal of women's health,* pp. 113-126, 2015.

[2] M. Abedalthagafi, S. Bawazeer, R. I. Fawaz, A. M. Heritage, N. M. Alajaji, and E. Faqeih, "Non-invasive prenatal testing: a revolutionary journey in prenatal testing," *Frontiers in Medicine,* vol. 10, p. 1265090, 2023.

[3] S. A. Devaney, G. E. Palomaki, J. A. Scott, and D. W. Bianchi, "Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis," *Jama,* vol. 306, no. 6, pp. 627-636, 2011.

[4] A. Salisbury, A. Pearce, K. Howard, and S. Norris, "Impact of Structural Differences on the Modeled Cost-Effectiveness of Noninvasive Prenatal Testing," *Medical Decision Making,* vol. 44, no. 7, pp. 811-827, 2024.

[5] P. Benn, H. Cuckle, and E. Pergament, "Non-invasive prenatal testing for aneuploidy: current status and future prospects," *Ultrasound in Obstetrics & Gynecology,* vol. 42, no. 1, pp. 15-33, 2013.

[6] S. Birko, M.-E. Lemoine, M. T. Nguyen, and V. Ravitsky, "Moving towards routine non-invasive prenatal testing (NIPT): challenges related to women's autonomy," *OBM Genetics,* vol. 2, no. 2, pp. 1-13, 2018.

[7] A. Kater-Kuipers, I. D. De Beaufort, R. J. H. Galjaard, and E. M. Bunnik, "Rethinking counselling in prenatal screening: an ethical analysis of informed consent in the context of non-invasive prenatal testing (NIPT)," *Bioethics,* vol. 34, no. 7, pp. 671-678, 2020.

[8] H. Strange, "Non-invasive prenatal diagnosis and testing: perspectives on the emergence and translation of a new prenatal testing technology," Cardiff University, 2015.

[9] K. B. Mullis and F. A. Faloona, "[21] Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction," in *Methods in enzymology*, vol. 155: Elsevier, 1987, pp. 335-350.

[10] B. J. Hindson *et al.*, "High-throughput droplet digital PCR system for absolute quantitation of DNA copy number," *Analytical chemistry,* vol. 83, no. 22, pp. 8604-8610, 2011.

[11] L. B. Pinheiro *et al.*, "Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification," *Analytical chemistry,* vol. 84, no. 2, pp. 1003-1011, 2012.

[12] J. F. Huggett *et al.*, "The Digital MIQE Guidelines: M inimum I nformation for Publication of Q uantitative Digital PCR E xperiments," *Clinical chemistry,* vol. 59, no. 6, pp. 892-902, 2013.

[13] C. M. Hindson *et al.*, "Absolute quantification by droplet digital PCR versus analog real-time PCR," *Nature methods,* vol. 10, no. 10, pp. 1003-1005, 2013.

[14] B. Demaree, D. Weisgerber, A. Dolatmoradi, M. Hatori, and A. R. Abate, "Direct quantification of EGFR variant allele frequency in cell-free DNA using a microfluidic-free digital droplet PCR assay," in *Methods in cell biology*, vol. 148: Elsevier, 2018, pp. 119-131.

[15] P.-L. Quan, M. Sauzade, and E. Brouzes, "dPCR: a technology review," *Sensors,* vol. 18, no. 4, p. 1271, 2018.

[16] G. Dong *et al.*, "Development and evaluation of a droplet digital PCR assay for the detection of fowl adenovirus serotypes 4 and 10 in attenuated vaccines," *Journal of Virological Methods,* vol. 265, pp. 59-65, 2019.

[17] X. Yang *et al.*, "Global trends in the application of droplet digital PCR technology in the field of infectious disease pathogen diagnosis: A bibliometric analysis from 2012 to 2023," *Diagnostic Microbiology and Infectious Disease,* vol. 111, no. 3, p. 116623, 2025.

[18] A. G. Sacher *et al.*, "Prediction of lung cancer genotype noninvasively using droplet digital PCR (ddPCR) analysis of cell-free plasma DNA (cfDNA)," ed: American Society of Clinical Oncology, 2014.

[19] Y. Cao, M. R. Raith, and J. F. Griffith, "Droplet digital PCR for simultaneous quantification of general and human-associated fecal indicators for water quality assessment," *water research,* vol. 70, pp. 337-349, 2015.

[20] T. J. Henrich, S. Gallien, J. Z. Li, F. Pereyra, and D. R. Kuritzkes, "Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR," *Journal of virological methods,* vol. 186, no. 1-2, pp. 68-72, 2012.

[21] A. S. Whale, J. F. Huggett, and S. Tzonev, "Fundamentals of multiplexing with digital PCR," *Biomolecular detection and quantification,* vol. 10, pp. 15-23, 2016.

[22] B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr, and K. W. Kinzler, "Cancer genome landscapes," *science,* vol. 339, no. 6127, pp. 1546-1558, 2013.

[23] R. M. Mitchell *et al.*, "Development of a new barcode-based, multiplex-PCR, next-generation-sequencing assay and data processing and analytical pipeline for multiplicity of infection detection of Plasmodium falciparum," *Malaria Journal,* vol. 20, pp. 1-16, 2021.

[24] W. Trypsteen *et al.*, "ddpcRquant: threshold determination for single channel droplet digital PCR experiments," *Analytical and bioanalytical chemistry,* vol. 407, pp. 5827-5834, 2015.

[25] S. Kraemer *et al.*, "From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay," *PloS one,* vol. 6, no. 10, p. e26332, 2011.

[26] B. Dong, Y. Lu, N. Zhang, W. Song, and W. Lin, "Ratiometric imaging of cysteine level changes in endoplasmic reticulum during H2O2-induced redox imbalance," *Analytical Chemistry,* vol. 91, no. 9, pp. 5513-5516, 2019.

[27] B. Zimmermann *et al.*, "Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci," *Prenatal diagnosis,* vol. 32, no. 13, pp. 1233-1241, 2012.

[28] G. R. Oxnard *et al.*, "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA," *Clinical cancer research,* vol. 20, no. 6, pp. 1698-1705, 2014.

[29] D. Marthaler, Y. Jiang, T. Otterson, S. Goyal, K. Rossow, and J. Collins, "Complete genome sequence of porcine epidemic diarrhea virus strain USA/Colorado/2013 from the United States," *Genome announcements,* vol. 1, no. 4, pp. 10.1128/genomea. 00555-13, 2013.

[30] D. Morisset, D. Štebih, M. Milavec, K. Gruden, and J. Žel, "Quantitative analysis of food and feed samples with droplet digital PCR," *PloS one,* vol. 8, no. 5, p. e62583, 2013.

[31] A. A. Koshkin *et al.*, "LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition," *tetrahedron,* vol. 54, no. 14, pp. 3607-3630, 1998.

[32] B. Vester and J. Wengel, "LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA," *Biochemistry,* vol. 43, no. 42, pp. 13233-13241, 2004.

[33] Y. You and B. Chapman, "Small area estimation using area level models and estimated sampling variances," *Survey Methodology,* vol. 32, no. 1, p. 97, 2006.

[34] E. Mazaika and J. Homsy, "Digital droplet PCR: CNV analysis and other applications," *Current protocols in human genetics,* vol. 82, no. 1, pp. 7.24. 1-7.24. 13, 2014.

[35] G. Nixon, J. A. Garson, P. Grant, E. Nastouli, C. A. Foy, and J. F. Huggett, "Comparative study of sensitivity, linearity, and resistance to inhibition of digital and nondigital polymerase chain reaction and loop mediated isothermal amplification assays for quantification of human cytomegalovirus," *Analytical chemistry,* vol. 86, no. 9, pp. 4387-4394, 2014.

[36] R. Owczarzy, Y. You, C. L. Groth, and A. V. Tataurov, "Stability and mismatch discrimination of locked nucleic acid-DNA duplexes," *Biochemistry,* vol. 50, no. 43, pp. 9352-9367, 2011.

[37] R. B. Parikh *et al.*, "Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer," *International Journal of Radiation Oncology* Biology* Physics,* vol. 89, no. 4, pp. 880-887, 2014.

[38] M. Homs *et al.*, "Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution," *PLoS One,* vol. 9, no. 11, p. e112306, 2014.

[39] R. W. Chiu, "Noninvasive prenatal testing by maternal plasma DNA analysis: Current practice and future applications," *Scandinavian Journal of Clinical and Laboratory Investigation,* vol. 74, no. sup244, pp. 48-53, 2014.

[40] J. Mianné *et al.*, "Analysing the outcome of CRISPR-aided genome editing in embryos: Screening, genotyping and quality control," *Methods,* vol. 121, pp. 68-76, 2017.

[41] S. Perlado, A. Bustamante-Aragonés, M. Donas, I. Lorda-Sánchez, J. Plaza, and M. Rodríguez de Alba, "Fetal genotyping in maternal blood by digital PCR: towards NIPD of monogenic disorders independently of parental origin," *PloS one,* vol. 11, no. 4, p. e0153258, 2016.

[42] D. Liang *et al.*, "Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing," *Prenatal diagnosis,* vol. 33, no. 5, pp. 409-415, 2013.

[43] L. S. Chitty and Y. D. Lo, "Noninvasive prenatal screening for genetic diseases using massively parallel sequencing of maternal plasma DNA," *Cold Spring Harbor perspectives in medicine,* vol. 5, no. 9, p. a023085, 2015.

[44] R. Flower *et al.*, "Droplet digital pcr for fetal HPA-1A typing-NIPT proof of principle study," *Pathology,* vol. 52, pp. S111-S112, 2020.

[45] Y. Guo, P. Charoenkwan, K. Traisrisilp, W. Piyamongkol, and F. Tongprasert, "Application of Digital Polymerase Chain Reaction (dPCR) in Non-Invasive Prenatal Testing (NIPT)," *Biomolecules,* vol. 15, no. 3, p. 360, 2025.

[46] R. C. Caswell *et al.*, "Noninvasive fetal genotyping by droplet digital PCR to identify maternally inherited monogenic diabetes variants," *Clinical chemistry,* vol. 66, no. 7, pp. 958-965, 2020.

[47] L. Qiao *et al.*, "Sequencing of short cfDNA fragments in NIPT improves fetal fraction with higher maternal BMI and early gestational age," *American Journal of Translational Research,* vol. 11, no. 7, p. 4450, 2019.

[48] J. Shaw *et al.*, "Non-invasive fetal genotyping for maternal alleles with droplet digital PCR: A comparative study of analytical approaches," *Prenatal Diagnosis,* vol. 43, no. 4, pp. 477-488, 2023.

[49] S. Laššáková *et al.*, "Rapid non-invasive prenatal screening test for trisomy 21 based on digital droplet PCR," *Scientific Reports,* vol. 13, no. 1, p. 22948, 2023.

[50] A. K. Mittal, D. S. Shekhawat, M. Patel, P. Singh, and K. Singh, "Economic implications of ddPCR and NGS-based noninvasive prenatal testing for fetal aneuploidy screening," *International Journal of Public Health,* vol. 13, no. 4, pp. 1809-1818, 2024.

[51] X. Mao, C. Liu, H. Tong, Y. Chen, and K. Liu, "Principles of digital PCR and its applications in current obstetrical and gynecological diseases," *American journal of translational research,* vol. 11, no. 12, p. 7209, 2019.

[52] K. A. Chan *et al.*, "Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing," *Proceedings of the National Academy of Sciences,* vol. 110, no. 47, pp. 18761-18768, 2013.

[53] S. Nambisan, M. Wright, and M. Feldman, "The digital transformation of innovation and entrepreneurship: Progress, challenges and key themes," *Research policy,* vol. 48, no. 8, p. 103773, 2019.

[54] Y. Zhou *et al.*, "Effects of maternal and fetal characteristics on cell-free fetal DNA fraction in maternal plasma," *Reproductive Sciences,* vol. 22, no. 11, pp. 1429-1435, 2015.

[55] H. C. Fan, W. Gu, J. Wang, Y. J. Blumenfeld, Y. Y. El-Sayed, and S. R. Quake, "Non-invasive prenatal measurement of the fetal genome," *Nature,* vol. 487, no. 7407, pp. 320-324, 2012.

[56] I. Hudecova *et al.*, "Maternal plasma fetal DNA fractions in pregnancies with low and high risks for fetal chromosomal aneuploidies," *PloS one,* vol. 9, no. 2, p. e88484, 2014.

[57] J. Wang, D. Duncan, Z. Shi, and B. Zhang, "WEB-based gene set analysis toolkit (WebGestalt): update 2013," *Nucleic acids research,* vol. 41, no. W1, pp. W77-W83, 2013.

[58] S. C. Yu *et al.*, "Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing," *Proceedings of the National Academy of Sciences,* vol. 111, no. 23, pp. 8583-8588, 2014.

[59] P. Jiang *et al.*, "FetalQuantSD: accurate quantification of fetal DNA fraction by shallow-depth sequencing of maternal plasma DNA," *NPJ genomic medicine,* vol. 1, no. 1, pp. 1-7, 2016.

[60] S. S. Chim *et al.*, "Detection of the placental epigenetic signature of the maspin gene in maternal plasma," *Proceedings of the National Academy of Sciences,* vol. 102, no. 41, pp. 14753-14758, 2005.

[61] S. S. Chim *et al.*, "Detection and characterization of placental microRNAs in maternal plasma," *Clinical chemistry,* vol. 54, no. 3, pp. 482-490, 2008.

[62] Y. Xiang *et al.*, "Investigation of a salmonellosis outbreak caused by multidrug resistant Salmonella Typhimurium in China," *Frontiers in Microbiology,* vol. 11, p. 801, 2020.

[63] Y. Ge *et al.*, "MUC1 is associated with TFF2 methylation in gastric cancer," *Clinical Epigenetics,* vol. 12, pp. 1-10, 2020.

[64] T. D. Snyder, C. De Brey, and S. A. Dillow, "Digest of Education Statistics 2014, NCES 2016-006," *National Center for Education Statistics,* 2016.

[65] P. Ulz *et al.*, "Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection," *Nature communications,* vol. 10, no. 1, p. 4666, 2019.

[66] K. R. van der Meij *et al.*, "TRIDENT-2: national implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the Netherlands," *The American Journal of Human Genetics,* vol. 105, no. 6, pp. 1091-1101, 2019.

[67] Y. Zhao *et al.*, "Prenatal fine particulate matter exposure, placental DNA methylation changes, and fetal growth," *Environment International,* vol. 147, p. 106313, 2021.

[68] M. Brunetti *et al.*, "Endometrial carcinoma: molecular cytogenetics and transcriptomic profile," *Cancers,* vol. 14, no. 14, p. 3536, 2022.

[69] L. S. Chitty *et al.*, "Right or wrong? Looking through the retrospectoscope to analyse predictions made a decade ago in prenatal diagnosis and fetal surgery," *Prenatal Diagnosis,* vol. 40, no. 13, pp. 1627-1635, 2020.

[70] G. D. Perkins *et al.*, "Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial," *Jama,* vol. 327, no. 6, pp. 546-558, 2022.

[71] H. Zimmermann, M. Zebisch, and N. Sträter, "Cellular function and molecular structure of ecto-nucleotidases," *Purinergic signalling,* vol. 8, pp. 437-502, 2012.

[72] J. F. Huggett, S. Cowen, and C. A. Foy, "Considerations for digital PCR as an accurate molecular diagnostic tool," *Clinical chemistry,* vol. 61, no. 1, pp. 79-88, 2015.

[73] S. R. Bang-Christensen *et al.*, "Capture and detection of circulating glioma cells using the recombinant VAR2CSA malaria protein," *Cells,* vol. 8, no. 9, p. 998, 2019.

[74] B. Demaree, D. Weisgerber, F. Lan, and A. R. Abate, "An ultrahigh-throughput microfluidic platform for single-cell genome sequencing," *Journal of Visualized Experiments: JoVE,* no. 135, p. 57598, 2018.

[75] S. W. Mes *et al.*, "Comprehensive multiparameter genetic analysis improves circulating tumor DNA detection in head and neck cancer patients," *Oral Oncology,* vol. 109, p. 104852, 2020.

[76] F. Garlan *et al.*, "Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study)," *Clinical Cancer Research,* vol. 23, no. 18, pp. 5416-5425, 2017.

[77] A. Srinivasan, D. W. Bianchi, H. Huang, A. J. Sehnert, and R. P. Rava, "Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma," *The American Journal of Human Genetics,* vol. 92, no. 2, pp. 167-176, 2013.

[78] O. Lopes Abath Neto *et al.*, "MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevated serum creatine kinase," *Brain,* vol. 144, no. 9, pp. 2722-2731, 2021.

[79] Z. Yu, Z. Zhao, L. Chen, J. Li, and X. Ju, "Development of a droplet digital PCR for detection of Trichuriasis in sheep," *The Journal of Parasitology,* vol. 106, no. 5, pp. 603-610, 2020.

[80] S. Shin, S. Han, J. Kim, Y. Shin, J.-J. Song, and S. Hohng, "Fast, sensitive, and specific multiplexed single-molecule detection of circulating tumor DNA," *Biosensors and Bioelectronics,* vol. 242, p. 115694, 2023.

[81] A. Wu *et al.*, "Genome-wide plasma DNA methylation features of metastatic prostate cancer," *The Journal of clinical investigation,* vol. 130, no. 4, pp. 1991-2000, 2020.

[82] I. Neefs *et al.*, "Simultaneous detection of eight cancer types using a multiplex droplet digital PCR assay," *Molecular Oncology,* vol. 19, no. 1, pp. 188-203, 2025.

[83] K. L. Y. Wong *et al.*, "Adoption of artificial intelligence-enabled robots in long-term care homes by health care providers: scoping review," *JMIR aging,* vol. 7, no. 1, p. e55257, 2024.

DrillBit

The Report is Generated by DrillBit Plagiarism Detection Software



Submission Information

Author Name	Ishita
Title	Droplet Digital Polymerase Chain Reaction (ddPCR) Approach for Sensitive and Non-Invasive Detection of Fetal Genetic Abnormalities
Paper/Submission ID	4163609
Submitted by	atul.upadhyay@thapar.edu
Submission Date	2025-07-30 15:43:20
Total Pages, Total Words	74, 15662
Document type	Thesis

Result Information

Similarity **11 %**

Sources Type



Report Content



Exclude Information

Quotes	Not Excluded
References/Bibliography	Not Excluded
Source: Excluded < 14 Words	Not Excluded
Excluded Source	0 %
Excluded Phrases	Not Excluded

Database Selection

Language	English
Student Papers	Yes
Journals & publishers	Yes
Internet or Web	Yes
Institution Repository	Yes

A Unique QR Code use to View/Download/Share Pdf File